1Abbreviated Title: Pembrolizumab in MTC
CC Protocol #: 17-C-0061
Version Date: 3.26.[ADDRESS_671779] #: [STUDY_ID_REMOVED]
Amendment :D
Title: Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid 
Cancer
NCI Principal Investigator: [INVESTIGATOR_131708] A. Madan, M.D.Genitourinary Malignancies Branch (GMB)National Cancer Institute10 Center DriveBuilding 10, Room 13N240Bethesda, MD 20892Phone: (301) 480-7168Email: [EMAIL_191]
Commercial Agent: Pembrolizumab will be supplied by [CONTACT_3455], [COMPANY_006]
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
2PRÃ‰CIS 
Background:
xAnti PD1/PDL1 therapi[INVESTIGATOR_517908] a mi nority of unselected patients 
across multiple tumor types
xWhile many questions remain about optimal PD1/PDL1 staining  techniques to pre-select 
responders, less focus is being place on how to  optimize responses in a broader cohort of 
patients
xEmerging preclinical and clinical data s upports the hypothesis that a strong immunologic 
response in the tumor microenvironment induc es PDL1 expression on the tumor and is 
associated with better clinical re sponse to anti-PD1/PDL1 therapi[INVESTIGATOR_517909], thereby [CONTACT_517936]1 expression and optimizing clinical responses across all 
patients
xLimited clinical data exists about the poten tial benefit of  sequential therapy with a 
therapeutic cancer vaccine followed by [CONTACT_4002]1/PDL1 inhibition
xThis study will explore the role of PD1 inhibition in medullary thyroid cancer and 
evaluate the potential differences based on previous vaccine therapy
Objective:
xThe primary objective of this trial is to determine whether administering a PD1 inhibitor to patients with medullary thyroid cancer will permit a modest fraction to be able to experience a 50% or greater decline in calcit onin levels or experience a partial/complete
response on imaging 
Key Eligibility:
xPatientsÂ•\HDUVRIDJH with evidence of metastatic medullary thyroid cancer including 
disease that is evaluable on bone, CT scan or MRI
xMust have elevated calcitonin levels greater than 40 pg/mL
xPatients with minimal or no disease related-symptoms (minimal symptoms will include those that do not affect activities of daily living or pain that does not require regularly schedule narcotics)
xECOG 0-[ADDRESS_671780] no autoimmune diseases; no evidence of being immunocompromised; no serious inter-current medical illness
xNo brain metastasis, history of seizures, encephalitis, or multiple sclerosis
Design:
xThis is a phase II, open label, single center clinical trial where all patients receive the 
anti-PD1/PDL1 therapy pembrolizumab
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
3xPatients will enroll in one of two cohorts:  patients with pr evious vaccine therapy or 
patients without previous vaccine therapy
xAll patients will be TKI -naÃ¯ve, with minimal symptoms (consistent with the eligibility 
for our current study)
xBased on our calcitonin findings with our current study of [ADDRESS_671781] 
determined that a confirmed calcitonin decline of 50% would be a rare finding, providing 
compelling preliminary evidence of clinical activity
xA total of [ADDRESS_671782] udy (15 patients in each cohort).
Given that we already have [ADDRESS_671783] >6 months of calcitoni n data in 30 patients within 
2 years from trial initiation
xAdditional immune correlative capi[INVESTIGATOR_517910] T-cells and 123
immune subsets.  These findings could provi de the basis for biomarker development 
when taken together with bi ochemical and clinical responses seen in this study
SCHEMA
Treatment Duration with Pembrolizumab: 2 years (at 3 week intervals)

Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
4TABLE OF CONTENTS
PRÃ‰CIS........................................................................................................................................... 2  
SCHEMA........................................................................................................................................ 3  
TABLE OF CONTENTS.............................................................................................................. .. 4 
1 INTRODUCTION .................................................................................................................. 8  
1.1 Study Objectives .............................................................................................................. 8  
1.1.1  Primary Objectives.................................................................................................... 8  
1.1.2  Secondary Objectives................................................................................................ 8  
1.2 Background and Rationale ............................................................................................... 8  
1.2.1  Rationale for Dose Selection/Regimen/Modification............................................. 17  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT....................................................... 19  
2.1 Eligibility Cr iteria .......................................................................................................... 1 9 
2.1.1  Inclusion Criteria .................................................................................................... 19  
2.1.2  Exclusion Criteria ................................................................................................... 20  
2.1.3  Recruitment Strategies............................................................................................ 22  
2.2 Registration Procedures.................................................................................................. 22  
2.3 Screening Evaluation...................................................................................................... 23  
2.3.1  The following tests may be obtained any time prior to initiation of study therapy:23  
2.3.2  The following parameters will be obtained  within 8 weeks prior to initiation of 
study therapy:........................................................................................................................ 23  
2.3.3  The following parameters will be obtained  within 10 days prior to initiation of 
study therapy:........................................................................................................................ 23  
2.4 Treatment Assignment and Randomization/Stratification Procedures: ......................... 24  
2.5 Baseline Evaluation........................................................................................................ 24  
3 STUDY IMPLEMENTATION ............................................................................................ 25  
3.1 Study Design .................................................................................................................. 25  
3.2 Trial Treatments ............................................................................................................. 25  
3.3 Drug Administration ...................................................................................................... 25  
3.3.1  Dose Modifications................................................................................................. 26  
3.3.2  Dosing Delay .......................................................................................................... 28  
3.4 Study Calendar ............................................................................................................... 29  
3.5 Criteria for Removal from Protocol Therapy and Off Study Criteria............................ 31  
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
53.5.1  Criteria for removal from protocol therapy ............................................................ 31  
3.5.2  Off-Study Criteria ................................................................................................... 31  
3.5.3  Off Protocol Therapy and Off-Study Procedure..................................................... 31  
4 CONCOMITANT MEDICATIONS/MEASURES.............................................................. 32  
4.1.1  Acceptable Concomitant Medications .................................................................... 32  
4.1.2  Prohibited Concomita nt Medications ..................................................................... 32  
4.1.3  Supportive Care Guidelines .................................................................................... 33  
5 BIOSPECIMEN COLLECTION.......................................................................................... 36  
5.1 Collection of Research (Immunologic) Blood Samples (all patients)............................ 36  
5.1.1  Immunologic Parameters (every 3 weeks unless not logistically feasible) ............ 37  
5.1.2  Natural Killer (NK) CELLS.................................................................................... 37  
5.1.3  Immune Subsets...................................................................................................... 37  
5.1.4  Regulatory T Cells .................................................................................................. 37  
5.1.5  Additional Assays ................................................................................................... 38  
5.1.6  Biopsy analysis by [CONTACT_12387] (Optional). ........................................ 38  
5.1.7  Immunohistochemistry ........................................................................................... 38  
5.2 Sample Storage, Tracking and Disposition.................................................................... 38  
5.2.1  Procedures for storage of tissue specimens in the Laboratory of Pathology .......... 38  
5.2.2  Blood Processing Core - Storage ............................................................................ 39  
5.2.3  Samples Sent to Clinical Services Program (CSP)................................................. 40  
5.2.4  Protocol Completion/Sample Destruction .............................................................. 41  
6 DATA COLLECTION AND EVALUATION..................................................................... 42  
6.1 Data Coll ection............................................................................................................... 42  
6.2 Data Sharing Plans ......................................................................................................... 43  
6.2.1  Human Data Sharing Plan....................................................................................... 43  
6.2.2  Genomic Data Sharing Plan.................................................................................... 43  
6.3 Response Criteria ........................................................................................................... 44  
6.3.1  Serum Calcitonin .................................................................................................... 44  
6.3.2  Imaging ................................................................................................................... 44  
6.3.3  Disease Parameters ................................................................................................. 46  
6.3.4  Methods for Evaluation of Measurable Disease ..................................................... 47  
6.3.5  Duration of Response.............................................................................................. 49  
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
66.3.6  Progression-Free Survival....................................................................................... 49  
6.4 Toxicity Criteria ............................................................................................................. 49  
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN
49 
7.1 Definitions.................................................................................................................... .. 49  
7.1.1  Adverse Event......................................................................................................... 49  
7.1.2  Suspected adverse reaction ..................................................................................... 50  
7.1.3  Unexpected adverse reaction .................................................................................. 50  
7.1.4  Serious..................................................................................................................... 50  
7.1.5  Serious Adverse Event............................................................................................ 50  
7.1.6  Disability................................................................................................................. 50  
7.1.7  Life-threatening adverse drug experience............................................................... 51  
7.1.8  Protocol Deviation (NIH Definition)...................................................................... 51  
7.1.9  Non-compliance (NIH Definition).......................................................................... 51  
7.1.10  Unanticipated Problem............................................................................................ 51  
7.2 NCI-IRB and Clinical Director (CD)  Reporting ............................................................ 51  
7.2.1  NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problems and Deaths51
 
7.2.2  NCI-IRB Requirements for PI [INVESTIGATOR_10021] ........................... 51  
7.3 Safety Reporting Criteria to th e Pharmaceutical Collaborator....................................... 52  
7.3.1  Serious Adverse Events .......................................................................................... 52  
7.3.2  Reporting of Overdose............................................................................................ 52  
7.3.3  Reporting of Pregnancy and Lactation ................................................................... 52  
7.4 Data and Safety Monitoring Plan................................................................................... 53  
7.4.1  Principal Investigator/Research Team .................................................................... 53  
8 STATISTICAL CONSIDERATIONS.................................................................................. 53  
9 COLLABORATIVE AGREEMENTS ................................................................................. 54  
9.1 Clinical Trials Agreement (CTA) .................................................................................. [ADDRESS_671784] Selection ................................................................................. 54  
10.2  Participation of Children ............................................................................................ 54  
10.3  Participation of Subjects Un able to Give Consent ..................................................... 54  
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
710.4  Evaluation of Benefits and Risks/Discomforts........................................................... 55  
10.4.1  Optional Biopsies.................................................................................................... 55  
10.5  Risks/Benefits Analysis.............................................................................................. 55  
10.6  Consent Process and Documentation ......................................................................... 55  
10.6.1  Telephone Re-Consent Procedure........................................................................... 56  
10.6.2  Informed Consent of Non-English Speaking Subjects ........................................... 56  
10.7  Contracep tion.............................................................................................................. 56  
10.8  Use In Pregnancy........................................................................................................ 58  
10.9  Use In Nursing Women .............................................................................................. 58  
11 PHARMACEUTICAL INFORMATION............................................................................. 58  
11.1  Pembrolizumab (MK-3475) ....................................................................................... 58  
11.1.1  Source ..................................................................................................................... 58  
11.1.2  Toxicity................................................................................................................... 59  
11.1.3  Formulation and preparation................................................................................... 61  
11.1.4  Stability and Storage............................................................................................... 61  
11.1.5  Administration procedures...................................................................................... 62  
11.1.6  Incompatibilities ..................................................................................................... 62  
11.1.7  Clinical Supplies Disclosure................................................................................... 62  
11.1.8  Returns and Reconciliation..................................................................................... 63  
12 APPENDIX A: PERFORMANCE STATUS CRITERIA.................................................... 64  
13 APPENDIX B: INSTRUCTIONS FOR PRE-STUDY AND FOLLOW-UP BLOOD TESTS
65 
14 REFERENCES ..................................................................................................................... 66  
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671785] fraction to be able to experience a 50% or greater decline in calcitonin levels or experience partial/c omplete response on imaging. Based on our 
calcitonin findings with our current study of [ADDRESS_671786] determined that aconfirmed calcitonin decline of 50% would be a rare finding, providing compelling preliminary evidence of clinical activity.
1.1.[ADDRESS_671787] on progression free survival and overall survival
xEvaluate the safety of anti-PD1/PDL1 therapy pembrolizumab
1.2 Background and Rationale
Background
Therapi[INVESTIGATOR_517911]1/PD1 axis have become the primary focus of clinical 
immunotherapy development as a substantial amount of academic and industry resources are 
being used to develop these therapi[INVESTIGATOR_014].  Several diseases have been noted for their impressive responses in individual patients (bladder cancer, lung cancer and melanoma) and emerging data suggest benefit across a broad range of tumors.  Despi[INVESTIGATOR_517912], regardless of tumor type, only a minority of patients have response to this therapy.
1A lot of effort is being 
expended to develop a biomarker predicting response (such as PDL1 expression by [CONTACT_7879]) but techniques and standards remain elusive.   A key focus of this study is to determine if therapeutic cancer vaccines can enhance responses to pembrolizumab, providing a proof of concept that sequential therapy with vaccine followed by [CONTACT_517937].  If this hypothesis is correct, this study could define a technique substantially enhance the proportion of patients who respond the immune checkpoint inhibition with agents such as pembrolizumab.
Medullary Thyroid Cancer
Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular or C 
cells of the thyroid gland. MTC accounts for a pproximately 4% of thyroid carcinomas. Its 
estimated incidence in the [LOCATION_002] for 2010 is about 1,300 to 2,200 patients. Sporadic MTC 
accounts for about 80% of all cases of the disease. The typi[INVESTIGATOR_517913]: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671788] largely 
been disappointing. These procedures may yield no  tumor resection and are unlikely to provide a 
biochemical remission. Patients w ith rapi[INVESTIGATOR_517914] < 2 years should be considered for treatme nt, ideally in the context of 
a well-designed clinical trial.5
Metastatic MTC is largely unresponsive to conventional cytotoxic chemotherapy and 
radiotherapy.6Until recently, doxorubicin was the only US Food and Drug Administration 
(FDA)â€“approved treatment for patients with adva nced thyroid cancer. Doxorubicin has resulted 
in transient tumor response rates in up to 20% of patients with MTC and is associated with significant toxicity.
[ADDRESS_671789] been re ported with vandetanib, an oral  inhibitor of VEGFR, RET, 
and epi[INVESTIGATOR_3506] (EGFR).8,9An international randomized phase III trial of 
vandetanib (300 mg daily) was perfor med in patients with either sporadic or hereditary MTC. In 
a preliminary report of results (median follow-up 24 months), median progression-free survival was improved in patients randomly assigned to vandetanib ve rsus placebo (hazard ratio 0.45, 
95% CI 0.30 to 0.69). 
10Based on these results, vandetanib was approved by [CONTACT_163881] 
2011 for patients with late-stage (metastatic) MTC who are ineligible for surgery and who have 
disease that is growing or causing symptoms.11Its toxicity profile is ex tensive including diarrhea 
(56%), rash (45%) nausea (33%), hypertension (32%) headache (26%), fatigue (24%), decreased appetite (21%); Grade 3 toxicities include diarrhea (11%), hypertension (9%) and fatigue (6%).  Therefore, toxicity limits its use in patients with small volume, asymptomatic or indolent disease.
Similarly cabozantinib has demonstrated improve ment in PFS in a population of patients 
with advanced MTC (estimated median PFS was 11.2 months for cabozantinib versus 4.0 months for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001) and is now FDA 
approved in MTC.
12Unfortunately, toxicity was also significant with this treatment with 
common associated adverse events including diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and fatigue. The impact of toxicity on the patients was clearly indicated based on the fact that 70% of patients required dos e reductions and dosing 
delays in 65% of patients.
Given the toxicity with these FDA approved agents, patients and practitioners alike often 
delay treatment until patients have symptoms commensurate with the toxicity profile or a rapid pace of disease.  As demonstrated by [CONTACT_517938] (30 patients in about 2.5 years) which enrolls patients who are naÃ¯ve to thes e TKIs, accruing to this population is feasible, 
representing a therapeutic window of opportunity for the proposed study. 
Vaccine Therapy with GI-[ADDRESS_671790]- CEA vaccine has completed accrual at the
NCI.
13A total of 25 patients enrolled in a classic phase I design at 3 dose levels: 4, 16, and 40 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671791] units (divided in 4 injection sites/ each unit =107yeast particles). GI-[ADDRESS_671792] patients 
were heavily pre-treated with advanced diseas e, a situation in which GI-6207 induced immune 
response can be difficult to generate. 
Of 25 evaluable patients, 5 patients (3 colon cancer, 1 MTC and 1 non-small cell lung 
cancer) had stable disease beyond 3 months (18, 10, 8, 5, 4 months, respectively).  All [ADDRESS_671793] commo n adverse event (AE) was grade [ADDRESS_671794] of toxicity (all grades) is listed in Table 1 . One patient 
with MTC, who had a large pericardial (5 cm) and pleural based (over 3 cm) mass, developed 
pleural and pericardial effusions (with associated pneumonitis, dyspnea) that may have been 
associated with a robust anti-tumor immune res ponse. (These symptoms resolved within 48 hour 
after steroids were administered).  Another pa tient with NSCLC developed recurrent pleural 
effusion which responded to oral steroids. The grade 3 back and abdominal pain were observed 
in a patient with rapi[INVESTIGATOR_517915]-existing ascites which was more likely the cause of these two events.
Table 1: Phase I CEA yeast toxicities  (all grade toxicities with  attribution 3 or higher) 
GRADE 1 GRADE 2 GRADE 3
AE #  pts #  events # pts #  events # pts #  events
Abdominal Pain [ADDRESS_671795] 0 0 1 1 0 0
Fatigue 5 5 0 0 0 0
Fever 1 1 1 1 1 1
Flu-like syndrome 3 3 1 1 0 0
Flushing 1 1 0 0 0 0
Headache 1 1 1 1 0 0
Hypoxia 0 0 0 0 1 1
Injection site reaction 12 34 1 6 0 0
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
11GRADE 1 GRADE 2 GRADE 3
AE #  pts #  events # pts #  events # pts #  events
Myalgia 2 2 1 1 0 0
Nausea 1 1 0 0 0 0
Pain 1 1 0 0 1 1
Thrombocytopenia 1 1 0 0 0 0
Pleural Effusion 0 0 1 1 1 1
Proteinuria 1 1 0 0 0 0
Pruritis 1 1 0 0 0 0
Rash 0 0 1 1 0 0
Pneumonitis 0 0 0 0 1 1
Immune Responses with GI-6207
Although this was a heavily pre-treated populat ion of patients with advanced disease, 
there were some immunologic parameters that suggested GI-6207 induced an immune response.  
Interferon-gamma ELISPOT assays (CEA and MUC1) were performed in [ADDRESS_671796]- vaccination. Antigen- specific T-cell responses were detected (a 
minimum of a 2-fold increase from baseline) in 5 out of 9 patients. One of these patients was the MTC who had a greater than 20-fold increases in  antigen-specific T-cell responses compared to 
baseline. The number and phenotype of NK cells was determined by [CONTACT_517939]56, CD3, 
and CD16 in 13 patients. NK cells may represent increased innate activity of the immune system after GI-6207.  Six of 13 evaluable patients had increased, 5 had unchanged and 2 had decreased 
NK frequency. 3 out of 4 evaluable patients with stable had increased NK frequency (including 
patient with MTC).
Treg levels were determined by 7-color flow cytometry analysis using CD4, CD25, 
CD127, FoxP3, CTLA-4, CD45RA, and CD8. Effe ctor/Treg ratios (pre - vs. post GI-6207
administration) were calculated in 16 evaluabl e patients. Eight of 16 evaluable patients had 
increased Effector/Treg ratio, suggesting that T- cells were more active after treatment.  MDSC 
(myeloid-derived suppressor cell) frequency (mo nocytic and granulocytic) were determined in 
[ADDRESS_671797] had substantial inflammatory responses.  One is pi[INVESTIGATOR_280915].
13A second 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
12patient in the current MTC trial has had a similar epi[INVESTIGATOR_517916], but now 
declining calcitonin.
Figure 1. Inflammatory response in a patient with  medullary thyroid cancer who was treated with 
vaccine. Frames A and B: Baseline computed tomography (CT) of a patient with medullary thyroid cancer who had a pericardial-based lesi on (a, arrow) and a right-sided pleural-based 
lesion (b, arrow). Frame C: Six days after the seventh vaccine (approximately 13 weeks after 
initiating therapy), the patient developed shortness of breath and was admitted to a local hospi[INVESTIGATOR_307]. CT showed a right-sided pleural effusion an d a pericardial effusion. A biopsy evaluating 
lymphangitic spread, bronchoscopy with lavage, and empi[INVESTIGATOR_517917]. With no clear diagnosis, high-dose steroids were started to treat a potential immune-related reaction. The patientâ€™s sy mptoms resolved within 48 h. Frame D: CT image obtained 18 
days after the image in (C) and approximately [ADDRESS_671798] allergies an d found to be negative, and the magnitude of 
antigen-specific T cell response to multiple tumor antigens increased 10- to 20-fold after vaccine. Based on the clinical course and absence of an alternative diagnosis, it is possible that this was a vigorous immune-mediated antitumor response. Inte restingly, in image (C), the effusion was 
only on the right side (arrow), the same location of the pleural-based lesion seen in (B)
13
Rationale for Using Vaccines to Enha nce Responses to PD1/PDL1 blockade
Unlike targets of other precision therapi[INVESTIGATOR_014], PDL1 expression is not a somatic mutation 
that is inherent to the cancer itself.  PDL1 expression is dynamic and likely a reaction of the cancer cells to immune cells in the tumor microenvironment. One can think of it as a â€œfootprintâ€ suggesting an activated T-cell response was or is there
14.  Thus PDL1/PD1 inhibitors are 
essentially enabling neutralized immune cells already in the tumor microenvironment to by[CONTACT_517940]: Pembrolizumab in MTC
Version Date: 3/26/18
13the tissue preserving inhibitory T-cell signaling through PD1/PDL1 and kill cancer cells.  There 
is actually substantial evidence from colon cancer, that the presence of immune cells in resected samples is strongly associated with clinical outc omes, demonstrating the potential clinical impact 
of immune activity against cancer cells.
15Similar data is also emerging across many other 
tumor types.16Taken a step further, cancer cells that can neutralize immune cells, perhaps with 
immune checkpoint inhibitors such as PDL1 have a greater likelihood of clonal propagation within a patient.  
Figure 2: Effect of Vaccin ation on Tumor PD-L1 Expression
One study done in the LTIB (unpublished, Greiner Lab) demonstrates that vaccine can 
indeed enhance tumor expression by [CONTACT_20405].  These studies included a CEA-targeting 
vaccine and two cell line, MC38 (pi[INVESTIGATOR_5832]) and Lewis Lung cancer
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671799] implicated INF- Jas one mediator PDL1 expression by [CONTACT_20405].  INF- Jis a 
cytokine produced by [CONTACT_93247] T-cells, and thus biologically it would seem that it is a rational 
mechanistic trigger for PDL1 expression.  Preclini cal and clinical data supports this hypothesis.
17,18Preclinical studies evaluating established B16 tumors in C57BL/6, Balb/c mice
demonstrated that vaccine combined with anti-PDL1 therapy had the greatest impact on tumor growth compared to vaccine or controls alone.  Interestingly, that benefit was negated when an 
antibody binding to INF- Jwas introduce into the model, demonstrating its important role in the 
synergy of the two therapi[INVESTIGATOR_014].  Also, interesting findings were noted when human tumors were 
evaluated for INF- JTissue in melanoma patients that had increased genetic expression of genes 
consistent with INF- Jproduction were associated with the greatest responses to anti-PD1 
therapy.
Based on this perspective, combining or sequencing vaccines with anti-PDL1/PD1 
therapi[INVESTIGATOR_517918] a greater proportion of patients that are 
currently unable to benefit from immune ch eckpoint inhibition. Increasing peripheral T-cell 
activation with vaccines, thereby [CONTACT_517941]-PDL1/PD1 therapi[INVESTIGATOR_014].  
Figure 3.  Vaccines may prime the tumor mic roenvironment to increase response rate to 
anti-PD1 inhibitors.
Case Report: Patient who received Vaccine and then a PD1/PDL1 Checkpoint Inhibitor
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
15Figure 4
This case report in Figure 4 is (unpublished) data from a male with MTC who was 
surveilled for 6 months prior to getting 4 months of vaccine.  During surveillance he had 
doubling time (one method to measure tumor growth rate) of approximately 135 days.  During the vaccine period his doubling time improved/was prolonged to approximately 530 days.  He then came off vaccine for elective surgery and per protocol had to discontinue vaccine.  When seen in follow up, his calcitonin was rising again after surgery.  At that point, approximately 3 months after surgery, he enrolled on a PDL1 inhibitor with a calcitonin of 9765 pg/ml.  (Calcitonin stabilization after surgery may vary based on disease burden, but within 1 month it would be expected to achieve maximum decline.
19He then had 5 consecutive declines in his 
calcitonin to 5732 pg/ml while on the immune checkpoint inhibitor, a greater than 40% decline.  At this time, he had an immune related advers e event (asymptomatic rise in lab values) that 
required discontinuation of therapy.  With extensive toxicity data from pembrolizumab, in the proposed phase II trial PD1/PDL1 inhibition would not be discontinued for asymptomatic lab 
values such as the case in this patient who was on a phase I trial which has stricter guidelines.
Although this patientâ€™s peripheral immune response has not been evaluated yet, his 
lymph node with tumor resected at surgery was evaluated for PDL1 expression.  The staining of this sample was robustly positive for PDL1 expression.  (No baseline sample was available for evaluation given that patient was diagnosed over 15 years ago.)
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
16Figure 5. Robustly positive PDL1 staining after surgical resection of a neck lymph node after 
vaccine (higher power on the right.)
These data suggest that a patient with a rapi[INVESTIGATOR_517919], had his calcitonin 
doubling time slowed (improved) while on vaccine. The vaccine was discontinued per protocol as the patient elected to have surgical resection, but after a transient decline in calcitonin, his values began to rise again. At this point he enrolled on a clinical trial of an immune checkpoint inhibitor targeting the PD1/PDL1 axis and had a rapid, substantial (>40%) decline in his calcitonin.  While on the phase I trial of the ch eckpoint inhibitor, the patient had asymptomatic 
changes in lab values, which led to protocol mandated treatment discontinuation.  This decline in terms of percentage and consecutive values demonstrating a confirmed decline has not been seen in any of the [ADDRESS_671800] immune surveillance in controlling outgrowth of neoplastic 
transformation has been known for decades.  Accumulating evidence shows a correlation between tumor-infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in various malignancies.  In particular, the presence of CD8+ T-cells and the ratio of CD8+ effector T-cells / FoxP3+ regulatory T-cells seems to correlate with improved prognosis and long-term survival in many solid tumors.
The PD-[ADDRESS_671801] hijacked by [CONTACT_13207].  The normal function of PD-1, expresse d on the cell surface of activated T-cells under 
healthy conditions, is to down-modulate unwante d or excessive immune responses, including 
autoimmune reactions.  PD-1 (encoded by [CONTACT_13228]1) is an Ig superfamily member related 
to CD28 and CTLA-4 which has been shown to negatively regulate antigen receptor signaling upon engagement of its ligands (PD-L1 and/or PD-L 2).  The structure of murine PD-1 has been 
resolved.  PD-1 and family members are type I transmembrane glycoprotei ns containing an Ig 
Variable-type (V-type) domain responsible for ligand binding and a cytoplasmic tail which is 
responsible for the binding of signaling molecule s.  The cytoplasmic tail of PD-1 contains 2 
tyrosine-based signaling motifs, an immunoreceptor tyrosine-based inhibition motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM).  Following T-cell stimulation, PD-1recruits the tyrosine phosphata ses SHP-1 and SHP-2 to the ITSM motif within its cytoplasmic 
WDLOOHDGLQJWRWKHGHSKRVSKRU\ODWLRQRIHIIHFWRUPROHFXOHVVX FKDV&'È—3.&È™ and ZAP70 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671802] from that of CTLA-4 as both molecules 
regulate an overlappi[INVESTIGATOR_77971].  PD-1 was s hown to be expressed on activated 
lymphocytes including peripheral CD4+ and CD8+  T-cells, B-cells, T re gs and Natural Killer 
cells.  Expression has also been shown dur ing thymic development on CD4-CD8- (double 
negative) T-cells as well as subsets of macrophages and dendritic cells.  The ligands for PD-1
(PD-L1 and PD-L2) are constitutively expressed or  can be induced in a variety of cell types, 
including non-hematopoietic tissues  as well as in various tumors.  Both ligands are type I 
transmembrane receptors containing both IgV- and IgC-like domains in the extracellular region and contain short cytoplasmic regions with no k nown signaling motifs.  Binding of either PD-[ADDRESS_671803] notably on vascular 
endothelium, whereas PD-L2 protein is only det ectably expressed on antigen-presenting cells 
found in lymphoid tissue or chronic inflammatory environments.  PD-L2 is thought to control 
immune T-cell activation in lymphoid organs, wher eas PD-L1 serves to dampen unwarranted T-
cell function in peripheral tissu es.  Although healthy organs express little (if any) PD-L1, a 
variety of cancers were demonstrated to express abundant levels of this T-cell inhibitor.  PD-1
has been suggested to regulate tumor-specific T-cell expansion in subjects with melanoma (MEL).  This suggests that the PD-1/PD-L1 pathway plays a critical role in tumor immune evasion and should be considered as an a ttractive target for therapeutic intervention.
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.  Pembrolizumab
TM (pembrolizumab) has recently been approved in the United 
Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipi[INVESTIGATOR_77972], if BRAF V600 mutation positive, a BRAF inhibitor.
1.2.1 Rationale for Dose Selec tion/Regimen/Modification
An open-label Phase I trial (Proto col 001) is being conducted to ev aluate the safety and clinical 
activity of single agent pembrolizumab (MK-3475) .  The dose escalation portion of this trial 
evaluated three dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every 2 weeks 
(Q2W) in subjects with advanced solid tumors.  All three dose levels were well tolerated and no dose-limiting toxicities were observed.  This first in human study of pembrolizumab (MK-3475)showed evidence of target engagement and objectiv e evidence of tumor size reduction at all dose 
levels (1 mg/kg, 3 mg/kg and 10 mg/kg Q2W).  No MTD has been identified to date.  10.0 
mg/kg Q2W, the highest dose tested in PN001, will be the dose and schedule utilized in Cohorts 
A, B, C and D of this protocol to test for initial tumor activity.  Recent data from other clinical studies within the pembrolizumab (MK-3475) program has shown that a lower dose of pembrolizumab (MK-3475) and a less frequent schedule  may be sufficient for target engagement 
and clinical activity.
PK data analysis of pembrolizumab (MK- 3475) administered Q2W and Q3W showed slow 
systemic clearance, limited volume of distributi on, and a long half-life (refer to IB).  
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
18Pharmacodynamic data (IL-2 release assay) sugge sted that peripheral target engagement is 
durable (>21 days).  This early PK and pharmaco dynamic data provides sc ientific rationale for 
testing a Q2W and Q3W dosing schedule.  
A population pharmacokinetic analysis has been performed using serum concentration time data 
from 476 patients. Within the resulting population PK model, clearance and volume parameters 
of pembrolizumab (MK-3475) were found to be dependent on body weight. The relationship 
between clearance and body weight, with an a llometric exponent of 0.59, is within the range 
observed for other antibodies and would support bo th body weight normalized dosing or a fixed 
dose across all body weights.  Pembrolizumab  (MK-3475) has been found to have a wide 
therapeutic range based on the melanoma indica tion.  The differences in exposure for a 200 mg 
fixed dose regimen relative to a 2 mg/kg Q3W body weight based regimen are anticipated to remain well within the establishe d exposure margins of 0.5 â€“ 5.0 for
 pembrolizumab (MK-3475)
in the melanoma indication. The exposure margins are based on the notion of similar efficacy 
and safety in melanoma at 10 mg/kg Q3W vs. th e proposed dose regimen of 2 mg/kg Q3W (i.e. 
5-fold higher dose and exposure). The populati on PK evaluation revealed that there was no 
significant impact of tumor burden on exposure.  In addition, exposure was similar between the 
NSCLC and melanoma indications. Therefore, th ere are no anticipated changes in exposure 
between different indication settings.
The rationale for further exploration of 2 mg/ kg and comparable doses of pembrolizumab in 
solid tumors is based on: 1) similar efficacy and safety of pembrolizumab when dosed at either 2 
mg/kg or 10 mg/kg Q3W in melanoma patients202) the flat exposure-re sponse relationships of 
pembrolizumab for both efficacy and safety in the dose ranges of 2 mg/kg Q3W to 10 mg/kg Q3W, 3) the lack of effect of tumor burd en or indication on distribution behavior of 
pembrolizumab (as assessed by [CONTACT_517942]) and 4) the assumption that the 
dynamics of pembrolizumab target engagement will not vary meaningfully with tumor type.
The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on 
simulations performed using the population PK m odel of pembrolizumab showing that the fixed 
dose of 200 mg every 3 weeks will provide exposures  that 1) are optimally consistent with those 
obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as a ssociated with maximal efficacy response and 3) 
will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe. 
A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and 
to reduce potential for dosing errors.  A fixed dosing scheme will also reduce complexity in the logistical chain at treatment facilities and reduce wastage.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
192 ELIGIBILITY ASSESSMENT AND ENROLLMENT
2.1 Eligibility Criteria2.1.1 Inclusion Criteria
[IP_ADDRESS] Diagnosis:  Patients must have histologic ally confirmed medullary thyroid cancer 
by [CONTACT_517943] a pathology report and history consistent with 
medullary thyroid cancer.  It is not unc ommon for a secondary, minor pathologic 
focus of another form of thyroid cancer to be coincidentally found in 15-20% of 
patients with medullary thyroid cancer
21.  In such cases, eligibility is based on the 
discretion of the investigator.   
[IP_ADDRESS] Patients must have eviden ce of metastatic medullary thyroid cancer including 
disease that is evaluable on bone, CT scan  or MRI. (Patients who are surgical 
candidates and potentially rendered disease free with surgical resection are not 
eligible.) 
[IP_ADDRESS] Patients must have elevated calc itonin levels greater than 40 pg/mL 
[IP_ADDRESS] Patients must have minimal or no diseas e related-symptoms (Minimal symptoms 
will include those that do not affect activities of daily living or pain that does not 
require regularly scheduled narcotics.)
[IP_ADDRESS] Patients must have evaluable disease on imaging
[IP_ADDRESS] No history of seizures, en cephalitis, or multip le sclerosis.
[IP_ADDRESS]$JHÂ•\HDUV
[IP_ADDRESS] ECOG performance status of 0-1 at study entry ( .DUQRIVN\Â• (See Appendix 
A).
[IP_ADDRESS] Female subject of childbearing potentia l should have a negative urine or serum 
pregnancy within [ADDRESS_671804] will be required.  
[IP_ADDRESS] Female subjects of childbearing potential mu st be willing to use an adequate method of 
contraception as outlined in Section 10.6, Contraception, for the course of the study 
through [ADDRESS_671805] dose of study medication.Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception 
for the subject
[IP_ADDRESS] Male subjects of childbearing potential mu st agree to use an adequate method of 
contraception as outlined in Section 10.6, Contraception, starting with the first 
dose of study therapy through [ADDRESS_671806] dose of study therapy.
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
[IP_ADDRESS] Willing to travel to the NIH for follow-up visits
[IP_ADDRESS] Able to understand and sign informed consent.[IP_ADDRESS] Demonstrate adequate orga n function as defined in Table 2 , all screening labs should be 
performed within 10 days of treatment initiation.  
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
20Table 2 Adequate Organ Function Laboratory Values
System Laboratory Value
Hematological
Absolute neutrophil count (ANC) Â•000 /mcL
Platelets Â•PF/
HemoglobinÂ•JG/RUÂ•PPRO/ without transfusion or EPO 
dependency (within 7 days of assessment)
Renal
Serum creatinine OR
Measured or calculatedacreatinine 
clearance
(GFR can also be used in place of 
creatinine or CrCl)Â”;XSSHUOLPLWRIQRUPDO8/1 OR
Â•P/PLQIRUVXEMHFWZLWKFUHDWLQLQHOHYHOV!;
institutional ULN
Hepatic
Serum total bilirubin Â”;8/1 OR
'LUHFWELOLUXELQÂ”8/1IRUVXEMHFWVZLWKWRWDOELOLUXELQ
levels > 1.[ADDRESS_671807] (SGOT) and ALT (SGPT)Â”;8/1 OR
Â”[ADDRESS_671808] for subjects with liver metastases
Albumin >2.5 mg/dL
Coagulation
International Normalized Ratio (INR) 
or Prothrombin Time (PT)
Activated Partial Thromboplastin 
Time (aPTT)Â”;8/1XQOHVVVXEMHFWLVUHFHLY ing anticoagulant 
therapy
as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Â”;8/1XQOHVVVXEMHFWLVUHFHLYLQJDQWLFRDJXODQW
therapy
as long as PT or PTT is within therapeutic range of 
intended use of anticoagulants
aCreatinine clearance should be calculated per Cockcroft-Gault equation.
2.1.2 Exclusion Criteria
[IP_ADDRESS] Is currently participating and receiving st udy therapy or has participated in a study 
of an investigational agent and received study therapy or used an investigational 
device within [ADDRESS_671809] dose of treatment.
[IP_ADDRESS] Has a diagnosis of immunodeficiency or is  receiving systemic steroid therapy or 
any other form of immunosuppressive therapy within [ADDRESS_671810] dose 
of trial treatment.
[IP_ADDRESS] Has a known history of active TB   (Bacillus Tuberculosis)
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
[IP_ADDRESS] Hypersensitivity to pembrolizumab or any of its excipi[INVESTIGATOR_840].
[IP_ADDRESS] Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to 
VWXG\'D\RUZKRKDVQRWUHF RYHUHGLHÂ”*UDGHRUDWEDV HOLne) from adverse 
events due to agents administered more than 4 weeks earlier.  
[IP_ADDRESS] Has had prior targeted small molecule therapy, or radiation therapy within 2 
weeks prior to study Day 1 or who has not re FRYHUHGLHÂ”*UDGHRUDW
baseline) from adverse events due to a previously administered agent.
1RWH6XEMHFWVZLWKÂ”*UDGHQHXURSDWK\DUHDQH[FHSWLRQWRWKLVFULWHULRQDQGPD\
qualify for the study.
Note:  If subject received major surgery, they must have recovered adequately from 
the toxicity and/or complications from the intervention prior to starting therapy.  
[IP_ADDRESS] Has active autoimmune disease that has re quired systemic treatme nt in the past 2 
years (i.e. with use of disease modifying agents, corticosteroids or 
immunosuppressive drugs). Replacement ther apy (e.g., thyroxine, insulin, or 
physiologic corticosteroid replacement therapy for adrenal or pi[INVESTIGATOR_13002], etc.) is not considered a form of systemic treatment.
[IP_ADDRESS] Has known active central nervous system (CNS) metastases a nd/or carcinomatous 
meningitis.  Subjects with previously treated brain metastases may participate provided they are stable for 6 months (without evidence of progression by 
[CONTACT_517944]), have no evidence of new or 
enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.  This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.  
[IP_ADDRESS] Has history of (non-infectious) pneumonitis  that required steroids, evidence of 
interstitial lung disease or active, non-infectious pneumonitis..
[IP_ADDRESS] Has an active infection requiring systemic therapy.
[IP_ADDRESS] Has a history or current evidence of  any condition, therapy, or laboratory 
abnormality that might confound the results  of the trial, interfere with the 
subjectâ€™s participation for the full duration of the trial, or is not in the best interest 
of the subject to participate, in th e opi[INVESTIGATOR_80021].  
[IP_ADDRESS] Has known psychiatric or substance abus e disorders that would interfere with 
cooperation with the requirements of the trial.
[IP_ADDRESS] Is pregnant or breastfeeding, or expecting to conceive or father children within the 
projected duration of the trial, starting with the pre-screening or screening visit 
through [ADDRESS_671811] dose of trial treatment.
[IP_ADDRESS] Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
[IP_ADDRESS] Has Human Immunodeficiency Vi rus (HIV) (HIV 1/2 antibodies).
[IP_ADDRESS] Has active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA 
[qualitative] is detected).
[IP_ADDRESS] Has received a live vaccine within 30 da ys of planned start of study therapy
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
[IP_ADDRESS] Concurrent use of systemic steroids, except for physiologic doses of systemic 
steroid replacement or local  (topi[INVESTIGATOR_2855], nasal, eye drops or inhaled) steroid use. 
Limited doses of systemic steroids (e.g., in  patients with exacerba tions of reactive 
airway disease or to prevent IV contra st allergic reaction or anaphylaxis in 
patients who have known contra st allergies) are allowed.
[IP_ADDRESS] Serious inter-current medical illness which would interfere with the ability of the 
patient to carry out the treatment program. 
[IP_ADDRESS] Patients with second maligna ncy within 3 years of enrollment; Patients curatively 
treated non-melanoma skin cancers or carci noma in situ of the bladder, are not 
excluded.  Patients with MEN2 and a history of pheochromocytoma will also not 
be excluded.  In addition patients with  prostate cancer who do not require 
systemic therapy will not be excluded.  (A secondary, minor pathologic focus of another form of thyroid cancer may be coincidentally found in 15-20% of patients 
with medullary thyroid cancer.  In such cases, eligibility is based on the discretion of the investigator.)
[IP_ADDRESS] Patients with previous history of va ndetanib or cabozantinib treatment for more
than 28 days of treatment (patients have discon tinued treatment for 28 days before 
enrolling).
2.1.[ADDRESS_671812] CEA vaccine 
â€“ 13-C-0095.  Furthermore, many patients from the study who are still being seen at the NCI will return and enroll on this trial.
2.[ADDRESS_671813] register an eligible candidate with NCI Central Registration Office (CRO) within [ADDRESS_671814] from the website (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) indicating that the patient is being 
registered for screening and send via encrypted email to: NCI Central Registration Office [EMAIL_978] .  Once eligibility is confirmed after completion of 
screening studies, complete the remainder of th e form which is the eligibility checklist, 
indicating that the patient is being registered for treatment and email the completed registration 
checklist to the CRO at NCI Central Registration Office [EMAIL_978] .
After confirmation of eligibility at Central Regi stration Office, CRO staff will call pharmacy to 
advise them of the acceptance of the patient on the protocol prior to the release of any investigational agents.  Verification of Registratio n will be forwarded electronically via e-mail to 
the research team. A recorder is available during non-working hours. 
Subjects that do not meet screening criteria should be removed from the study following the 
procedure in section 3.5.3.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
232.3 Screening Evaluation
2.3.1 The following tests may be obtained any time prior to initiation of study therapy:
xPathological confirmation of diagnosis in the Laboratory of Pathology at the NIH 
Clinical Center prior to starting this study when possible. Pathology reports from 
other hospi[INVESTIGATOR_161501] a history consistent w ith medullary thyroid cancer will also be 
sufficient for documentation of pathological confirmation.
2.3.2 The following parameters will be obtained within 8 weeks prior to initiation of study 
therapy:
xHIV (anti HIV 1,2 antibody)
xHepatitis B (HBcAb IgM) and C (HCV antibody test)
xTc-99 whole body scintigraphy (bone scan)
xCT of neck/chest/abdomen/pelvis (MRI may be substituted at investigator discretion)
xElectrocardiogram (EKG)
2.3.3 The following parameters will be obtained within 10 days prior to initiation of study 
therapy:
[IP_ADDRESS] Clinical Evaluation
xHistory and physical examination including vital signs (blood pressure, pulse, 
respi[INVESTIGATOR_697], oxygen saturation
xECOG performance status (see Appendix A )
[IP_ADDRESS] Laboratory studies
xComplete blood count plus differential and platelet count
xChemistries (sodium, potassium, chloride, CO2, creatinine, glucose, BUN, albumin, calcium, magnesium, phosphorus, alk phos, ALT, AST, total bilirubin, direct bilirubin, LD, total protein, total CK and uric acid)  
xPT, PTT
xUrinalysis (may be omitted if patient is incontinent and cannot provide a urine 
sample)
xSerum calcitonin and CEA
xTSH
xUrine Beta-HCG for women of child-bearing age (repeated within 48 hours prior to 
treatment).  (Serum Beta-HCG may be done if urine is positive or inconclusive). 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
24Females of childbearing potential (FCBP): A female of childbearing potential is a 
sexually mature woman who:
a) Has not undergone a hysterectomy or bilateral oophorectomy
b) Has not been naturally postmenopausal for at least 24 consecutive months (i.e. 
has had menses at any time in the preceding 24 consecutive months).
c) Has a congenital or acquired condition that prevents childbearing
In addition, patients, both male and female, should be willing to practice effective birth control 
during the study and for four months following the last study treatment, unless they have had a 
prior hysterectomy, bilateral oophorectomy, congenital conditions associated with infertility or azoospermia.
2.4 Treatment Assignment and Randomization/Stratification Procedures: 
Cohorts
Number Name [CONTACT_62578]
[ADDRESS_671815] cohort Patients with prior vaccine therapy
2 Second cohort Patients without prior vaccine therapy
Arms
Number Name [CONTACT_62578]
1 Pembrolizumab Pembrolizumab treatment for 2 years at Q3W
Randomization and Arm Assignment
Patients will be enrolled to Cohort 1 (previous vaccine) or Cohort 2 (no previous vaccine) based 
on their treatment history.  This will be established at each patientsâ€™ screening visit and noted on the eligibility criteria. Patients in cohort 1 and cohort 2 will be directly assigned to Arm 1.
2.5 Baseline Evaluation
Screening evaluations performed within 8 weeks prior and within 10 days prior to treatment 
initiation will be used as baseline.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
253 STUDY IMPLEMENTATION
3.1 Study DesignThis will be an open label study in which all pati ents receive pembrolizumab.  Patients will be 
assigned to specific cohorts based on their previous treatment with an immune stimulating 
therapeutic cancer vaccine.
Treatment Duration with Pembrolizumab: 2 years (at 3 week intervals)
3.2 Trial Treatments
The treatment to be used in this trial is outlined below in Table 3
Table 3 Trial Treatment
Drug Dose/Potency Dose 
FrequencyRoute of 
AdministrationRegimen/Treatment 
PeriodUse
Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week 
cycleExperimental
Treatment Duration with Pembrolizumab: 2 years (3 week intervals)
Trial treatment should begin on the day of enrollment or as close as possible to that date.
3.3 Drug Administration
Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments 
have been completed as detailed on the Study Calendar (Section 3.4). Trial treatment may be 
administered up to 7 days before or after the scheduled Day 1 of each cycle due to administrative reasons.
All trial treatments will be administered on an outpatient basis.
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every 
effort should be made to target infusion timing to be as close to 30 minutes as possible.  
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
26However, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 
minutes: -5 min/+10 min). Premedication for patients who experience an infusion reactionshould be administered 60 minutes (+/- 30 minutes) prior to the infusion. 
The Pharmacy Manual contains specific instructions for the preparation of the pembrolizumab 
infusion fluid and administration of infusion solution. Pembrolizumab is administered through a 0.2 to 5 micron sterile, nonpyrogenic, low-protein binding inline or add-on filter. Do not infuse other mediations through the same infusion line.
3.3.1 Dose Modifications
Adverse events (both non-serious and serious) associated with pembrolizumab exposure may 
represent an immunologic etiology.  These adverse events may occur shortly after the first dose or several months after the last dose of treatment. Pembrolizumab must be withheld for drug-related toxicities and severe or life-threatening AEs as per Table 4 below. See Section 4 for
supportive care guidelines, including use of corticosteroids.
Table 4. Dose Modification Guidelines  for Drug-Related Adverse Events
ToxicityHold 
Treatment 
For GradeTiming for Restarting 
TreatmentTreatment Discontinuation
Diarrhea/Colitis2-3Toxicity resolves to Grade 0-
1Toxicity does not resolve within [ADDRESS_671816] 
dose
3-4Permanently discontinue
(see exception below)aPermanently discontinue
Type 1 diabetes 
mellitus (if new 
onset) or 
HyperglycemiaT1DM or 
3-4Hold pembrolizumab for new 
onset Type [ADDRESS_671817] 
dose or inability to reduce corticosteroid to 10 
mg or less of prednisone or equivalent per day 
within 12 weeks
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671818] 
dose or inability to reduce corticosteroid to 10 
mg or less of prednisone or equivalent per day 
within 12 weeks
4 Permanently discontinue Permanently discontinue
Note: Permanently discontinue for any severe or Grade [ADDRESS_671819] or ALT increases by [CONTACT_55559] 50% relative to baseline and lasts for at least 1 week then patients should be discontinued.
bIf symptoms resolve within one hour of stoppi[INVESTIGATOR_13056], the infusion may be restarted at 50% of the original 
infusion rate   (e.g., from 100 mL/hr to 50 mL/hr).  Otherwise dosing will be held until symptoms resolve and the 
subject should be premedicated for the next scheduled dose; Refer to Table 5 â€“ Infusion Reaction Treatment 
Guidelines for further management details.
cPatients with intolerable or persistent Grade [ADDRESS_671820] dose.
Dosing interruptions are permitted in the case of medical / surgical events or logistical reasons 
not related to study therapy (e.g., elective surgery, unrelated medical events, patient vacation, and/or holidays). Subjects should be placed back on study therapy within 6 weeks of the 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
28scheduled interruption. The reason for interruption should be documented in the patient's study 
record.
3.3.2 Dosing DelayDosing delay is permitted by 7 days before or after scheduled treatment for logistical purposes 
(given travel requirements of our patients).  If there are changes in the schedule, the subsequent dose may not be given less than 18 days later.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
293.4 Study Calendar
ProcedureScreening/
Baseline5Treatment Cycles ( 21 days +/- 7 days)1Cycle [ADDRESS_671821] 
Treatment6C1
D1C2
D1C3
D1C4
D1C5
D1C6
D1C7
D1C8
D1
History and PE X2X XXX XX X X X X
Vital signs X2X XXX XX X X X X
Performance 
ScoreX2
Height/Weight X3
HIV, Hep B, C X
Pregnancy Test (Urine or Serum beta-HCG)X
2
UA4X2
PT/INR and PTTX
2
Chemistries7X2X XXX XX X X X X
CBC X2X XXX XX X X X X
TSH X2XX XX X X X X
T/B/NK subsets X2X XXX XX X X X X
Tumor Markers:Calcitonin and 
CEAX
2X XXX XX X X X X
Correlative 
Research Studies (research bloods see Appendix 
B)X
continue at 3 month intervalsX8
Radiological Assessments (MRI or CT Neck, Ch/Abd/Pelvis, Bone Scan)
3X
continue at 3 month intervals
EKG 3Xcontinue at 3 month intervals X
Biopsy(optional)
[ADDRESS_671822] 18 days later
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671823] be done within 8 weeks prior to initiation of study therapy, and then will be done every 3 months while 
patients remain on study
4May be omitted if patient is incontinent and cannot provide a urine sample
5Baseline/Screening requirements may also be used for Day [ADDRESS_671824] treatment when logistically feasible (with a possible extension to 
4 weeks if logistically necessary). Patients will be of fered enrollment in the 04-C-0274 â€œFollow-Up Study of 
Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or other Immunotherapeutic Agentsâ€ once off study.
7 Chemistries: sodium, potassium, chloride, CO2, creatinine, glucose, BUN, albumin, calcium, magnesium, 
phosphorus, alkaline phosphatase, ALT, AST, total bilirubin, direct bilirubin, LD, total protein, total CK, uric acid
[ADDRESS_671825]-treatment samples may be obtained from consenting patients.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671826] dose of study therapy.
3.5.1 Criteria for removal from protocol therapy
xCompletion of protocol therapy
xClinical progression of disease based on increased symptoms or immune related response 
criteria (irRC) to also be implemented for disease progression as described in 6.3.2.
xGrade 3 or greater toxicity attributed to treatment that does not resolve to grade 1 within 
21 days from time of scheduled treatment.
xGrade 3 or greater autoimmune disease that threatens vital organs.
xIntercurrent illness or medical circumstances. If at any time the constraints of this 
protocol are detrimental to the patientâ€™s hea lth, the patient may be removed from protocol 
therapy and reasons for withdrawal will be documented.
xSubject decides to withdraw from the study (In this event, the reasons for withdrawal will
be documented)
xInvestigator discretion
xPositive pregnancy test
3.5.2 Off-Study Criteria
Patients will be removed from the study for the following:
xSubjects proceeds to alternative treatments
xDeath
xPatient requests to be taken off study. Re asons for withdrawal will be documented. 
xNoncompliance with protocol guidelines (patient removed at discretion of Principal 
Investigator).
xInvestigator decides to end the study
xScreen failure
Patients will be offered enrollment in the 04-C-0274  â€œFollow-Up Study of Subjects Previously 
Enrolled in Immunotherapy Studies Utilizing Gene Transfer or other Immunotherapeutic Agentsâ€
once off study.
3.5.[ADDRESS_671827] notify Central Registration Office (CRO) when a subject is taken off 
protocol therapy and when a subject is taken off-study. A Participant Status Updates Form from 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
32the web site (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted ema il to: NCI Central Registration Office 
[EMAIL_978] .
4 CONCOMITANT MEDICATIONS/MEASURES
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing trial.  If there is a clinical indication for one of these or other medications or vaccinations specifically prohibited during the trial, discontinuation from trial therapy or vaccination may be required.  The investigator may d iscuss any questions regarding this with the 
[COMPANY_006] Clinical team.  The final decision on any supportive therapy or vaccination rests with the investigator and/or the subject's primary physician. 
4.1.[ADDRESS_671828]â€™s welfare may be 
administered at the discretion of the investigator in keepi[INVESTIGATOR_12983].  All concomitant medication will be recorded on the case report form (CRF) 
including all prescription, over-the-counter (OTC),  herbal supplements, an d IV medications and 
fluids.  If changes occur during the trial period, do cumentation of drug dosa ge, frequency, route, 
and date may also be included on the CRF.
All concomitant medi cations received within [ADDRESS_671829] dose of tr ial treatment should be recorded for SAEs a as 
defined in Section 7.1.5.
4.1.2 Prohibited Concomitant MedicationsSubjects are prohibited from receiving the fo llowing therapi[INVESTIGATOR_80025] (including retreatment for post-complete response rela pse) of this trial:
xAntineoplastic systemic chemothe rapy or biological therapy 
xImmunotherapy not specified in this protocol
xChemotherapy not specified in this protocol
xInvestigational agents other than pembrolizumab
xRadiation therapy
oNote:  Radiation therapy to a symptomatic solitary lesion or to the brain may be 
allowed at the investigatorâ€™s discretion.
xLive vaccines within [ADDRESS_671830] dose of trial treatment and while participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671831]-Treatment Follow-up Phase.4.1.3 Supportive Care GuidelinesSubjects should receive appropriate supportive care measures as deemed necessary by [CONTACT_78017].  Suggested supportive care measures for the management of adverse events with potential immunologic etiology are outlined  below. Where appropriate, these guidelines 
include the use of oral or intravenous treatmen t with corticosteroids as well as additional anti-
inflammatory agents if symptoms do not improve with administration of corticosteroids.  Note that several courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is decreased. For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or viral infection, which might require additional supportive care. The treatment guidelines are intended to be applied when the investigatordetermines the events to be related to pembrolizumab. 
Note: if after the evaluation the event is determined not to be related, the investigator does not 
need to follow the treatment guidance (as outlined below). Refer to Section 3.3.1 for dose 
modification. 
It may be necessary to perform conditional procedur es such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. 
xPneumonitis :
oFor Grade 2 events , treat with systemic corticosteroids. When symptoms 
improve to Grade 1 or less, steroid tape r should be started and continued over no 
less than 4 weeks.
oFor Grade 3-4 events , immediately treat with intravenous steroids. Administer 
additional anti-inflammatory measures, as needed.
oAdd prophylactic antibiotics for opportunistic  infections in the case of prolonged 
steroid administration
.
xDiarrhea/Colitis :
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as 
diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as peritoneal signs and ileus).  
oAll subjects who experience diarrhea/colitis should be advised to drink liberal quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted via IV in fusion. For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis.
oFor Grade 2 diarrhea/colitis, administer oral corticosteroids 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
34oFor Grade 3 or 4 diarrhea/colitis, treat with intravenous steroids followed by 
[CONTACT_78018].
oWhen symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
xType 1 diabetes mellitus (if new onset, including diabetic ketoacidosis [DKA] RUÂ•
Grade 3 Hyperglycemia, if associated with ketosis (ketonuria) or metabolic acidosis 
(DKA)
oFor T1DM or Grade 3-4 Hyperglycemia
ÂƒInsulin replacement therapy is recommended for Type I diabetes mellitus 
and for Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria. 
ÂƒEvaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated hemoglobin, and C-peptide. 
xHypophysitis :
oFor Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 
1 or less, steroid taper shoul d be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is tapered.
oFor Grade 3-4 events, treat with an initial dose of IV corticosteroid followed by 
[CONTACT_78019]. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no  less than 4 weeks. Replacement of 
appropriate hormones may be required as the steroid dose is tapered.
xHyperthyroidism or Hypothyroidism :
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
oGrade 2 hyperthyroidism events (and Grade 2-4 hypothyroidism):
ÂƒIn hyperthyroidism, non-selective be ta-blockers (e.g. propranolol) are 
suggested as initial therapy.
ÂƒIn hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or liothyroinine, is indicated per standard of care.
oGrade 3-4 hyperthyroidism 
ÂƒTreat with an initial dose of IV corticosteroid followed by [CONTACT_78019]. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no  less than 4 weeks. Replacement of 
appropriate hormones may be required as the steroid dose is tapered.
xHepatic :
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
35oFor Grade 2 events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).
ÂƒTreat with IV or oral corticosteroids
oFor Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours. 
oWhen symptoms improve to Grade 1 or less, a steroid taper should be started and 
continued over no less than 4 weeks.
xRenal Failure or Nephritis :
oFor Grade 2 events, treat with corticosteroids.
oFor Grade 3-4 events, treat with systemic corticosteroids.
oWhen symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
xManagement of Infusion Reactions :
Signs and symptoms usually develop during or shortly after drug infusion and generally 
resolve completely within 24 hours of completion of infusion. 
Table 5 below shows treatment guidelines for subjects who experience an infusion reaction 
associated with administration of pembrolizumab (MK-3475).
Table 5. Infusion Reaction Treatment Guidelines
NCI CTCAE Grade Treatment Premedication at 
subsequent dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicatedIncrease monitoring of vital signs as 
medically indicated until the subject is deemed medically stable in the opi[INVESTIGATOR_8574].None
Grade 2
Requires infusion interruption 
but responds promptly to 
symptomatic treatment (e.g., 
antihistamines, NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated for < =24 hrsStop Infusion and monitor symptoms.
Additional appropriate medical therapy 
may include but is not limited to:
IV fluids
Antihistamines
NSAIDSAcetaminophen
Narcotics
Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opi[INVESTIGATOR_8574].
If symptoms resolve within one hour of stoppi[INVESTIGATOR_13056], the infusion may 
be restarted at 50% of the originalSubject may be 
premedicated 1.5h (Â± 30 
minutes) prior to infusion of 
pembrolizumab (MK-3475) 
with:
Diphenhydramine 50 mg po 
(or equivalent dose of 
antihistamine).
Acetaminophen 500-1000
mg po (or equivalent dose 
of antipyretic).
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
36NCI CTCAE Grade Treatment Premedication at 
subsequent dosing
infusion rate (e.g., from 100 mL/hr to 50 
mL/hr).  Otherwise dosing will be held 
until symptoms resolve and the subject should be premedicated for the next 
scheduled dose.
Subjects who develop Grade 2 toxicity 
despi[INVESTIGATOR_517920].
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapi[INVESTIGATOR_38194]/or brief interruption of infusion); 
recurrence of symptoms 
following initial improvement; 
hospi[INVESTIGATOR_12258] (e.g., renal impairment, pulmonary 
infiltrates)
Grade 4:
Life-threatening; pressor or 
ventilatory support indicatedStop Infusion.
Additional appropriate medical therapy 
may include but is not limited to:
IV fluids
AntihistaminesNSAIDS
Acetaminophen
Narcotics
Oxygen
PressorsCorticosteroids
Epi[INVESTIGATOR_517921].
Hospi[INVESTIGATOR_13021].
Subject is permanently discontinued 
from further trial treatment 
administration.No subsequent dosing
Appropriate resuscitation equipment should be available in the room and a physician readily available 
during the period of drug administration.
5 BIOSPECIMEN COLLECTION
5.1 Collection of Research (Immunol ogic) Blood Samples (all patients)
The amount of blood that may be drawn from adult patients (i.e., those persons 18 years of age 
or older) for research purposes shall not exceed 10.5 mL/kg or 550 mL, whichever is smaller, over any eight week period.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
375.1.1 Immunologic Parameters (every 3 week s unless not logistically feasible)
xLeukocyte CD3, CD4, CD8 subsets; CD4:CD8 ra tio will be drawn at baseline and at 
each visit when on treatment (prior to vaccine) and then at follow-up visit while the 
patient remains on trial
xAdditional studies will include but are no t limited to quantitative and qualitative 
assessments of regulatory T-cells, Natu ral Killers cells, and Myeloid Derived 
Suppressor Cells. 
xAssessment of serum levels of cytokines.
xImmunologic studies will be repeated more fr equently if clinically indicated, and any 
abnormalities potentially related to treatment will be followed until they have resolved, or have been determined not to be treatment-related.
xPeripheral blood mononuclear cells (PBMC): Intracellular cytokine staining assays for specific antigens may be done based on preliminary data.  
xPhenotypic and functional analysis of immune cell subsets by [CONTACT_4133].
[IP_ADDRESS] Collection of Specimens
6 (10mL) green top sodium heparin tubes for PBMC; 2 (8mL) SST tubes for serum sample.
5.1.2 Natural Killer (NK) CELLS
The number and phenotype of NK cells will be determined by [CONTACT_195243]56, CD3, CD8, and CD16 by [CONTACT_4133].5.1.[ADDRESS_671832] been reported in the peripheral blood mononuclear cells of patients with several types of tumors.  The number and phenotype of regulatory T-cells in peripheral blood mononuclear cells from patients in this study will be determined by 7-color flow cytometry analysis.  Cells will be resuspended in staining buffer (phosphate-buffered saline containing 3% fetal bovine serum) and stained for CD4, CD25, CD127, FoxP3, CTLA-4, CD45RA, and CD8.  The ratios between regulatory T-cells and CD4 effector cells and the ratios between  regulatory T-cells and CD8 Effector cells will 
also be analyzed.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
385.1.5 Additional Assays
Blood samples may be used for additional rese arch studies, which may include one of the 
following - phenotypic and functional analysis of immune-cell subsets and analyses for cytokines 
(IFN-È–,/-10, IL-12, IL-2, IL-4, etc.), chemokines, antibodies related to the tumor or vaccine,
tumor associated antigens related to the tumor or the vaccine, and/or other immune response markers.
5.1.6 Biopsy analysis by [CONTACT_12387] (Optional).When logistically feasible, pre-treatment and post-treatment samples may be obtained from 
consenting patients.  Potential analysis could include PD1/PDL1 expression and immune cell infiltration.
5.1.[ADDRESS_671833] the procedure.  Immunohistochemistry of these tissue specimens will be obtained for CD4, CD8, and FOX-P3.  In addition, phenotypic analysis of infiltrating immune cell s will be performed.
Immunohistologic grading schema of the lesions 
Score %positive cells of each subtype001 1-25%
2 26-50%
3 >50%
All staining will be categorized as being membrane or nuclear
5.2 Sample Storage, Trac king and Disposition 
Samples will be ordered in CRIS and tracked through a Clinical Trial Data Management system.
Should a CRIS screen not be available, the CRIS downtime procedures will be followed.Samples will not be sent outside NIH without IRB notification and an executed MTA.
5.2.1 Procedures for storage of tissue spec imens in the Laboratory of Pathology
Tissues designated for clinical diagnostics are transported to the Laboratory of Pathology (LP) 
where they are examined grossly and relevant portions are fixed, embedded in paraffin and sectioned and stained for diagnostic interpretation.  Unutilized excess tissues are stored for up to three months, in accordance with College of American Pathologists/Joint Commission on Accreditation of Healthcare Organizations (CAP/JCAHO) guidelines, and then discarded.  
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
39Following completion of the diagnostic workup, the slides and tissue blocks are stored 
indefinitely in the LPâ€™s clinical archives.  All specimens are catalogued and retrieved utilizingthe clinical laboratory information systems, in accordance with CAP/JCAHO regulations.  The use of any stored specimens for research purposes is only allowed when the appropriate IRB approval has been obtained.  In some cases, th is approval has been obtained via the original 
protocol on which the patient was enrolled.
5.2.2 Blood Processing Core - Storage
All samples sent to the Blood Pr ocessing Core (BPC) will be ba rcoded, with data entered and 
stored in the LABrador (aka LabSamples) utilized by [CONTACT_74908]. This is a secure program, with 
access to LABrador limited to de fined Figg lab personnel, who are issued individual user 
accounts. Installation of LABra dor is limited to computers specified by [INVESTIGATOR_124]. Figg. These 
computers all have a password restricted login screen. All Figg lab personnel with access to patient information annually complete the NI H online Protection of Human Subjects course. 
LABrador creates a unique barcode ID for every sample and sample box, which cannot be traced 
back to patients without LABrador access. The data recorded for each sample includes the 
patient ID, name, trial name/protocol number, time drawn, cycle time point, dose, material type, as well as box and freezer location. Patient dem ographics associated with the clinical center 
patient number are provided in the system. For eac h sample, there are notes associated with the 
processing method (delay in sample proce ssing, storage conditions on the ward, etc.).
Barcoded samples are stored in barcoded boxes in a locked freezer at either -20 or -80 qC
according to stability requirements.  These freezers  are located onsite in the BPC and offsite at 
NCI Frederick Central Repository Services (American Type Culture Collection (ATCC)) in Frederick, MD. Visitors to the laboratory are requi red to be accompanied by [CONTACT_517945]. 
Access to stored clinical samples is restricted. Samples will be stored until requested by a 
researcher named on the protoc ol. All requests are monitored and tracked in LABrador. All 
researchers are required to sign a form stating that the samples are only to be used for research purposes associated with this trial (as per the IRB approved protocol) and that any unused 
samples must be returned to the BPC. It is the responsibility of the NCI Principal Investigator [INVESTIGATOR_517922] a manner consistent with IRB approval.
Following completion of this study, samples will remain in storage as de tailed above. Access to 
these samples will only be granted following IRB approval of an additional protocol, granting the rights to use the material. 
If, at any time, a patient withdraws from the study and does not wish for their existing samples to 
be utilized, the individual must provide a written request. Following receipt of this request, the samples will be destroyed (or returned to the patient, if so requested), and reported as such to the IRB. Any samples lost (in transit or by a researcher) or destroyed due to unknown sample integrity (i.e. broken freezer allows for extensive sample thawing, etc.) will be reported as such to the IRB.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
40Sample barcodes are linked to patient demographics and limited clinical information. This 
information will only be provided to investigators listed on this protocol, via registered use of the 
LABrador. It is critical that the sample remains linked to patient information such as race, age, dates of diagnosis and death, and histological info rmation about the tumor, in order to correlate 
genotype with these variables.
5.2.3 Samples Sent to Clini cal Services Program (CSP)
The samples will be processed through: 
Clinical Services Program 
NCI Frederick Cancer Research and Development Center PO Box B Frederick, MD [ZIP_CODE] [PHONE_4231]
On days samples are drawn, Jen Bangh at CSP should be notified (phone: [301] 846-5893; fax 
[301] 846-6222). She will arrange same-day courier delivery of the specimens. 
The research samples will contain labels on the blood tubes that have the patient's initials, date of 
birth, the assigned protocol, and the date the sample was drawn. The transmittal forms accompanying the samples also contain the same information. 
Once a patientâ€™s treatment schedule has been determined, it should be faxed to Caroline Jochems
at the Laboratory of Tumor Immunology and Biology/ NIH (Fax: [301] 496-2756; phone: [301] 496-9573) for planning purposes.
All data associated with patient samples are prot ected by a secure databa se. All samples drawn at 
the NIH Clinical Center will be transported to the NCI Frederick Central Repository by [CONTACT_517946].
Samples will be tracked and managed by [CONTACT_195246]. All samples will be 
stored in liquid nitrogen. These freezers are lo cated at NCI Frederick Central Repository in 
Frederick, Maryland.
American Type Culture Collection (ATCC) manages the NCI-Frederick Central Repositories 
under subcontract to Leidos Biomedical Research, Inc. NCI-Frederick Central Repositories store, among other things, biological specimens in supp ort of NIH clinical studies. All specimens are 
stored in secure, limited access f acilities with sufficient security , back up and emergency support 
capability and monitoring to ensure long-term integrity of the specimens for research. 
ATCCâ€™s role is limited to clinical research databases and repositories containing patient 
specimens. ATCC does not conduct nor  has any vested interest in  research on human subjects, 
but does provide services and support the efforts of  its customers, many of which are involved in 
research on human subjects. 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671834] copy or on vial labels. 
Sample data is stored in the BioSpecimen Inventory System II (BSI). This inventory tracking 
system is used to manage the storage and retrieval of specimens as well as maintain specimen data. BSI is designed for controlled, concurrent access. It provides a real-time, multi-user environment for tracking millions of specimens. The system controls how and in what order database updates and searches are performed. This control prevents deadlocks and race 
conditions. For security, BSI has user password access, three types of user access levels, and 36 user permissions (levels of access) that can be set to control access to the system functions. BSI 
provides audit tracking for processes that are done to specimens including shippi[INVESTIGATOR_007], returning to 
inventory, aliquoting, thawing, additives, and other processes. BSI tracks the ancestry of specimens as they are aliquoted, as well as discrepancies and disc repancy resolution for 
specimens received by [CONTACT_195247].  If a spec imen goes out of the inventory, the system 
maintains data associated with the withdraw re quest. Vials are labeled with a unique BSI ID 
which is printed in both eye readable and bar code d format.  No patient specific information is 
encoded in this ID. 
Investigators are granted view, input and withdr aw authority only for their specimens. They may 
not view specimen data or access sp ecimens for which they have not  been authorized. Access to 
specimen storage is confined to repository staff. Visitors to the repositories are escorted by 
[CONTACT_195248].
5.2.4 Protocol Completion/ Sample Destruction
Once primary research objectives for the protocol are achieved, intramural researchers can 
request access to remaining samples, provided they have an IRB-approved protocol and patient consent.
Samples and associated data will be stored perm anently unless the patient withdraws consent. If 
the patient withdraws consent the participantâ€™s data will be excluded from future distributions, 
but data that have already been distributed for approved research use will not be able to be 
retrieved. The PI [INVESTIGATOR_517923] (ex. broken freezer or lack of dry ice in shippi[INVESTIGATOR_7788]) or if a patient chooses to withdraw his/her consent. Samples will also be reported as lost if they are lost in transit or misplaced by a researcher.  Freezer problems, lost samples or other problems associated with samples will also be reported to the IRB, the NCI Clinical Director, and the office of the CCR, NCI.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671835] protected 
electronic system (C3D) and ensuring data accuracy, consistency and timeliness. The principal 
investigator, associate investigators/research nurses and/or a contracted data manager will assist 
with the data management efforts. All data obtained during the conduct of the protocol will be 
kept in secure network drives or in approved alternative sites that comply with NIH security standards. Primary and final analyzed data will ha ve identifiers so that research data can be 
attributed to an individual human subject participant.
Clinical data will be entered in a secure electronic database, NCI C3D database, and hard copi[INVESTIGATOR_517924], secured areas.  Comple ted eligibility checklists (developed by [CONTACT_517947], CRO), patient information/registration forms, and blood sample flow sheets will also be stored.  Copi[INVESTIGATOR_517925].
Complete records must be maintained on each patient, including the hospi[INVESTIGATOR_195195], radiology reports, or physician's records.  These records will serve as the primary source material that forms the basis for the research record.  All relevant data will also be entered in a computer database from which formal analyses will be done.  
The primary source documentation will include: on-study information, including patient 
eligibility data and patient history; flow sheets, records of adverse events, specialty forms for pathology, radiation, or surgery; and off-study summary sheets, including a final assessment by [CONTACT_1963].
All adverse events, including clinically significant abnormal findings on laboratory evaluations, 
regardless of severity, will be followed until return  to baseline or stabilization of event. Patients 
will be followed for adverse events for at least [ADDRESS_671836].
An abnormal laboratory value will be recorded in the database as an AE only if the laboratory 
abnormality is characterized by [CONTACT_39132]:
xResults in discontinuation from the study
xIs associated with clinical signs or symptoms 
xRequires treatment or any other therapeutic intervention
xIs associated with death or another serious adverse event, including hospi[INVESTIGATOR_059]. 
xIs judged by [CONTACT_118443], the investigator will 
provide details about the action taken with resp ect to the test drug and about the patientâ€™s 
outcome.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
43End of study procedures: Data will be stored according to HHS, FDA regulations, and NIH 
Intramural Records Retention Schedule as applicable.
Loss or destruction of data: Should we become aware that a major breach in our plan to protect 
subject confidentiality and trial data has occurred, the IRB will be notified. 
6.2 Data Sharing Plans
6.2.1 Human Data Sharing PlanWhat data will be shared?
I will share human data generated in this research for future research as follows:
xDe-identified data in an NIH-funded or approved public repository.  
xDe-Identified data in BTRIS (automatic for activities in the Clinical Center)
xDe-identified or identified data with approved outside collaborators under appropriate 
agreements.
How and where will the data be shared? 
Data will be shared through:
xAn NIH-funded or approved public repository.  Insert name [CONTACT_138794]: clinicaltrials.gov .
xBTRIS (automatic for activities in the Clinical Center)
xApproved outside collaborators under appropriate individual agreements.
xPublication and/or public presentations.
When will the data be shared? 
xBefore publication.
xAt the time of publication or shortly thereafter.
6.2.2 Genomic Data Sharing Plan
No genomic data will be gathered as part of this study.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
446.3 Response Criteria
For the purposes of this study, patients should be re-evaluated for response per the study calendar
(3.4).  In addition to a baseline sca n, confirmatory scans should also  be obtained not less than [ADDRESS_671837] recent value will be considered the
baseline unless the primary investigator feels that the value is unreliable.  In this case a note will document the reason for not using that value at enrollment and identification of an alternative baseline (obtained within 8 weeks of enrollment) will be used.
In order to be considered to have a â€œCalcitonin Responseâ€ patients must have a >50% decline 
from designated baseline value that is then confirmed on a subsequent serum calcitonin 
assessment at least one week later.
6.3.[ADDRESS_671838] clinical observations of immune cell influx into tumor causing enlargement in 
some patients prior to sustained response, recently it has been suggested that clinical trials involving the use of immunotherapy use alternative guidelines, called immune related response criteria (irRC) to determine radiographic response or progression after therapy
22.  These 
recommendations have been used in recent clinical trials.  One study of 227 subjects with metastatic melanoma showed that the approximately 10% of patients who had PD by [CONTACT_517948], PR or SD by [CONTACT_251720] a similar overall survival as those patients who had SD, PR or CR by [CONTACT_119580]. The irRC was created using bidimensional measurements (as previously widely used in the WHO criteria).  We have taken the concepts of the irRC and combined them with the recently revised RECIST 1.[ADDRESS_671839] 
1.1 are (a) a requirement for confirmation of both progression and response by [CONTACT_135004] 4 weeks after initial imaging and (b) not automatic ally calling the appearance of new lesions 
progressive disease if the total measurable tumor burden has not met criteria for progressive disease.  
For immune-related response criteria (irRC), on ly index and measurable new lesions are taken 
into account.  At baseline tumor assessment on this trial, target lesions will be measured along 
the longest axis and the measurements will be summed, called sum of largest diameter (SLD).  These lesions must be a minimum of 10mm per lesion, maximum of 5 target lesions, maximum of 2 per organ system.  At each subsequent tumor assessment, the unidimensional measurement of target lesions and of new measureable lesions are added together to provide the total tumor burden:  As per the modified definitions below, all responses and progression except stable 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
45disease (SD) require confirmation on a consecutive scan at least 4 weeks from the initial 
observation). 
Definitions of irRC:
Response irRC
New measurable lesions Incorporated into tumor burden
New non-measurable 
lesions Do not define progression (but precludes irCR)
Non-index lesions Contributes to defining irCR (complete disappearance required)
Overall irCR 100% disappearance of all lesions, whether measurable or not, and no new lesions, in 
two consecutive observations not less than [ADDRESS_671840] reduction in short axis to <10mm.
Overall irPR Â•GHFUHDVH in SLD compared with baseline confirmed by a consecutive 
assessment at least [ADDRESS_671841] documentation
Overall irSD Not meeting criteria for irCR or irPR, in absence of irPD:  30% decrease in SLD 
compared with baseline cannot be established nor 20% increase compared with nadir.
Overall irPD At least 20% increase in SLD co mpared with nadir (minimum recorded tumor 
burden) and an increase of at least 5mm over the nadir, confirmed by a repeat, 
consecutive observations at least [ADDRESS_671842] documented.
Overall responses derived from changes in index, non-index and new lesions as demonstrated in 
the following table:
Measurable response Non-measurable response Overall response 
using irRC
Index and new, measurable 
lesions (tumor burden)* %Non-index lesions New, non-measurable 
lesions
Decrease 100 Absent Absent irCR&
Decrease 100 Stable Any irPR&
Decrease 100 Unequivocal 
progressionAny irPR&
'HFUHDVHÂ• Absent / Stable Any irPR&
'HFUHDVHÂ• Unequivocal 
progressionAny irPR&
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
46Decrease < 30 to increase < 20 Absent / Stable Any irSD
Decrease < 30 to increase < 20 Unequivocal 
progressionAny irSD
,QFUHDVHÂ• Any Any irPD
* Decreases assessed relative to baseline 
&Assuming response (irCR) and progression (irPD) are confirmed by a second, consecutive assessment at least 4 
weeks apart.
6.3.3 Disease Parameters
Evaluable disease:  Disease that can be evaluated on imaging but does not meet the measurable 
disease criteria below. 
Measurable disease: Measurable lesions are defined as those that can be accurately measured in 
at least one dimension (longest diameter to be recorded):
xBy [CONTACT_13190] x-ray: >20 mm;
xBy [CONTACT_3610]: 
oScan slice thickness 5 mm or under: as >10 mm
oScan slice thickness >5 mm: double the slice thickness
With calipers on clinical exam: >[ADDRESS_671843] be >[ADDRESS_671844] scan (CT scan slice thickness recommended to be no greater than 5 mm).  At 
baseline and in follow-up, only the short axis will be measured and followed.
Non-measurable disease.  All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or SDWKRORJLFDOO\PSKQRGHVZLWKÂ• 10 to <15 mm short axis), are considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by [CONTACT_462]), are considered as non-measurable.
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not 
be considered as malignant lesions (neither measurable nor non-measurable) since they are, by [CONTACT_108], simple cysts.
â€˜Cystic lesionsâ€™ thought to represent cystic metastases can be considered as measurable lesions, 
if they meet the definition of measurability desc ribed above. However, if non-cystic lesions are 
present in the same patient, these are preferred for selection as target lesions.
Target lesions. All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions and recorded 
and measured at baseline.  Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be 
those that lend themselves to reproducible repeated measurements.  It may be the case that, on 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671845] lesion which can be measured reproducibly should be selected.  A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be included in the sum, then only the short axis is  added into the sum.  The baseline sum diameters 
will be used as reference to further characterize any objective tumor regression in the measurable 
dimension of the disease.
Non-target lesions.  All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non-target lesions and should also be 
recorded at baseline.  Measurements of these lesions are not required, but the presence, absence, 
or in rare cases unequivocal progression of each should be noted throughout follow-up.
6.3.4 Methods for Evaluation of Measurable DiseaseAll measurements should be taken and recorded in  metric notation using a ruler or calipers.  All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is preferred to evaluation by [CONTACT_460](s) being followed cannot be imaged but are assessable by [CONTACT_461].
Clinical lesions: Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and t10 mm diameter as assessed using calipers 
(e.g., skin nodules).  In the case of skin lesions, documentation by [CONTACT_6775], including a 
ruler to estimate the size of the lesion, is recommended. 
Chest x-ray: Lesions on chest x-ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by [CONTACT_6776]. However, CT is preferable. Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is [ADDRESS_671846] slice thickness 
greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is also acceptable in certain situations (e.g. for body scans).  
Use of MRI remains a complex issue.  MRI ha s excellent contrast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which greatly 
impact image quality, lesion conspi[INVESTIGATOR_3934], and measurement.  Furthermore, the availability of MRI is variable globally.  As with CT, if an MRI is performed, the technical specifications of the scanning sequences used should be optimized for the evaluation of the type and site of disease.  Furthermore, as with CT, the modality used at follow-up should be the same as was used at baseline and the lesions should be measured/assessed on the same pulse sequence.  It is beyond the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all scanners, body parts, and diseases.  Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be performed with breath-hold scanning techniques, if possible.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671847]: At present, the low dose or attenuation correction CT portion of a combined PET-CT 
is not always of optimal diagnostic CT quality for use with RECIST measurements.  However, if 
the site can document that the CT performed as part of a PET-CT is of identical diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET-CT can be used for RECIST measurements and can be used interchangeably with conventional CT in accurately measuring cancer lesions over time.  Note, however, that the PET portion of the CT introduces additional data which may bias an investigator if it is not routinely or serially performed.  
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement.  Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later date and, because they are operator dependent, it cannot be guaranteed that the same technique and measuremen ts will be taken from one assessment to the 
next.  If new lesions are identified by [CONTACT_12153], confirmation by [CONTACT_12154].  If there is concern about radiation exposure at CT, MRI may be used instead of CT in selected instances.
Endoscopy, Laparoscopy: The utilization of these techniques for objective tumor evaluation is 
not advised.  However, such techniques may be useful to confirm complete pathological 
response when biopsies are obtained or to dete rmine relapse in trials where recurrence following 
complete response (CR) or surgical resection is an endpoint.
Cytology, Histology: These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases  (e.g., residual lesions in tumor types, such as 
germ cell tumors, where known residual benign tumors can remain).The cytological confirmation of the neoplastic or igin of any effusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable disease is 
mandatory to differentiate between response or stable disease (an effusion may be a side effect of the treatment) and progressive disease.
FDG-PET: While FDG-PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in 
assessment of progression (particularly possible 'new' disease).  New lesions on the basis of FDG-PET imaging can be identified according to the following algorithm: 
a. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of 
PD based on a new lesion.
b. No FDG-PET at baseline and a positive FDG-PET at follow-up:  If the positive FDG-
PET at follow-up corresponds to a new site of disease confirmed by [CONTACT_4654], this is PD.  If the positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up CT  scans are needed to  determine if there is truly progression 
occurring at that site (if so, the date of PD will be the date of the initial abnormal FDG-PET scan).  If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the basis of the anatomic images, this is not PD.
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy 
in cases where a residual radiographic abnormality is thought to represent fibrosis or scarring.  The use of FDG-PET in this circumstance should be prospectively 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671848] be acknowledged that both approaches may lead to false positive CR due to limitations of FDG-PET and biopsy resolution/sensitivity.
Note:  A â€˜positiveâ€™ FDG-PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image.
6.3.5 Duration of ResponseDuration of overall response:  The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichev er is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference for progressive 
disease the smallest measurements recorded since the treatment started).
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that progressive disease is objectively documented.
Duration of stable disease:  Stable disease is measured from the start of the treatment until the 
criteria for progression are met, taking as reference the smallest measurements recorded since the 
treatment started, including the baseline measurements. 
6.3.[ADDRESS_671849].
6.4 Toxicity CriteriaThe following adverse event management guidelines are intended to ensure the safety of each 
patient while on the study.  The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events  (CTCAE) version 4.[ADDRESS_671850] access to a copy of the CTCAE version 
4.0. A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site (http://ctep.cancer.gov/protocolDevelopmen t/electronic_applications/ctc.htm#ctc_40 ). 
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN
7.[ADDRESS_671851], including any abnormal sign (for 
example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the subjectâ€™s participation in research, whether or not considered related to the subjectâ€™s participation in the research.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
507.1.2 Suspected adverse reaction
Suspected adverse reaction means any adverse ev ent for which there is a reasonable possibility 
that the drug caused the adverse event. For the purposes of IND safety reporting, â€˜reasonable 
possibilityâ€™ means there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.
7.1.3 Unexpected adverse reactionAn adverse event or suspected adverse reaction is considered â€œunexpectedâ€ if it is not listed in 
the investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or elsewhere in the current application. "Unexpectedâ€ also refers to adverse events or suspected adverse reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation.
7.1.4 Serious 
An Unanticipated Problem or Protocol Deviation is serious if it meets the definition of a Serious 
Adverse Event or if it compromises the safety, welfare or rights of subjects or others.
7.1.5 Serious Adverse EventAn adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it results in any of the following:
xDeath,
xA life-threatening adverse drug experience
xInpatient hospi[INVESTIGATOR_517926]/birth defect.
xImportant medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_3767] a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
7.1.6 Disability
A substantial disruption of a personâ€™s ability to conduct normal life functions.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671852] caused death.
7.1.8 Protocol Deviation (NIH Definition)Any change, divergence, or departure from the IRB-approved research protocol.  7.1.9 Non-compliance (NIH Definition)The failure to comply with applicable NIH Human Research Protections Program (HRPP)
policies, IRB requirements, or regulatory requirements for the protection of human research subjects.
7.1.10 Unanticipated ProblemAny incident, experience, or outcome that:
xIs unexpected in terms of nature, severity, or frequency in relation to 
(a) the research risks that are described in the IRB-approved research protocol and 
informed consent document; Investigatorâ€™s Brochure or other study documents, and
(b) the characteristics of the subject population being studied; AND
xIs related or possibly related to participation in the research; AND
xSuggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized.
7.2 NCI-IRB and Clinical Director (CD)  Reporting
7.2.1 NCI-IRB and NCI CD Expedited Reportin g of Unanticipated Problems and Deaths
The Protocol PI [INVESTIGATOR_52341]-IRB and NCI CD:
xAll deaths, except deaths due to progressive disease
xAll Protocol Deviations
xAll Unanticipated Problems
xAll non-compliance
Reports must be received within 7 days of PI [INVESTIGATOR_10039].
7.2.2 NCI-IRB Requirements for PI [INVESTIGATOR_118378]-IRB: 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
521. A summary of all protocol deviations in a tabular format to include the date the deviation 
occurred, a brief description of the deviation and any corrective action.
2. A summary of any instances of non-compliance
3. A tabular summary of the following adverse events:
xAll Grade 2 unexpected events that are possibly, probably or definitely related to the 
research; 
xAll Grade 3 and 4 events that are possibly,  probably or definitely related to the
research; 
xAll Grade 5 events regardless of attribution; 
xAll Serious Events regardless of attribution. 
NOTE : Grade 1 events are not required to be reported. 
7.3 Safety Reporting Criteria to the Pharmaceutical Collaborator
7.3.1 Serious Adverse Events
The investigator should submit all serious adverse events on a Medwatch 3500 Form within 2 
working days of receipt to [COMPANY_006] Global Safety. (Attn: Worldwide Product Safety; FAX [PHONE_1209])
7.3.[ADDRESS_671853] be reported within 2 working 
days of receipt to [COMPANY_006] Global Safety. (Attn: Worldwide Product Safety; FAX [PHONE_1209])
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,000 mg 
RUJUHDWHUÂ•WLPHVWKHLQGLFDWHGGRVH No specific information is available on the treatment of 
overdose of pembrolizumab. Appropr iate supportive treatment shoul d be provided if clinically 
indicated. In the event of overdose, the subject sh ould be observed closely for signs of toxicity.  
Appropriate supportive treatme nt should be provided if  clinically indicated.
7.3.[ADDRESS_671854] (spontaneously reported to them) that occurs during the trial.
Pregnancies and lactations that occur after the consent form is signed but before treatment 
allocation/randomization must be reported by [CONTACT_26364], or are the result of a protocol-specified intervention, including but not limited to washout or discontinuation of usual ther apy, diet, placebo treatment or a procedure.  
Pregnancies and lactations that occur from the time of treatment allocation/randomization through 120 days following cessation of manufacturerâ€™s product, or [ADDRESS_671855] be followed to the completion/termination of 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671856] 
be reported as serious events (Important Medical Events). If the pregnancy continues to term, the outcome (health of infant) must also be reported.
Such events must be reported within 2 working days of receipt to [COMPANY_006] Global Safety. (Attn: 
Worldwide Product Safety; FAX [PHONE_1209]).
7.4 Data and Safety Monitoring Plan
7.4.1 Principal Investigator/Research Team 
The clinical research team will meet on a regular basis at least monthly when patients are being 
actively treated on the trial to discuss each patient. Decisions about dose level enrollment and dose escalation if applicable will be made base d on the toxicity data from prior patients. 
All data will be collected in a timely manner and reviewed by [CONTACT_1716][INVESTIGATOR_1660] [INVESTIGATOR_1660] a lead associate investigator. Adverse events will be reported as required above. Any safety concerns, new information that might affect either the ethical and or scientific conduct of the trial, or protocol deviations will be immediately reported to the IRB using iRIS.
The principal investigator [INVESTIGATOR_131729]. The principal investigator [INVESTIGATOR_338721]. 
[ADDRESS_671857] fraction to be able to experience a 50% or greater decline in calcitonin levels or experience a clinical res ponse by [CONTACT_506502]/complete 
response on imaging.
Patients on this trial w ill be enrolled into two cohorts: pa tients who have previously received 
vaccine and patients who have not  previously received vaccine. The results from each cohort will 
be considered individually.
In each cohort, the trial will be c onducted as a single stage pi[INVESTIGATOR_517927] 15 evaluable patients. It 
is expected that this regimen will result in a limited fraction of patients who experience a 50% or 
greater decline in calcitonin levels or experien ce a clinical response by [CONTACT_517949]/complete response 
on imaging. If the true probability that patients will experience a 50% decline in calcitonin or respond is 10%, there is only 5.6% probability or having 4 or more of 15 do so, while if the true probability is 40% or more, there is 90.9% or gr eater probability of observing [ADDRESS_671858] fraction with 50% or greater decline in 
calcitonin levels or respond than  if fewer patients in a cohort ex perience this decline or respond. 
A 95% confidence interval will also be formed about the observed proportion of patients who experience a 50% or greater decline or respond, and the actual decline pe rcentages for patients 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
54on both cohorts will be re ported descriptively, as well as th e fraction who experience a clinical
response. With limited numbers of patients in this trial, there w ill be low power to do a formal 
comparison of the two cohorts; information about  the proportion with subs tantial declines or 
responses in either cohort may be used to guide de velopment of future trials using this approach.
It is anticipated that 1 patient per month may en roll onto this trial. Thus, to obtain 30 evaluable 
patients, approximately 2 to 3 years of accrual is anticipated. In order to allow for a small 
number of inevaluable patients, the accr ual ceiling will be set to 32 patients.
9 COLLABORATIVE AGREEMENTS
9.1 Clinical Trials Agreement (CTA)
This study will be conducted with [COMPANY_006] as part of a Clinical Trials Agreement (CTA), CTA#
[ZIP_CODE]-17.
[ADDRESS_671859] benefit from research participation (section 10.5), all subjects Â•DJH will be offered the opportunity to fill 
in their wishes for research and care, and assign a substitute decision maker on the â€œNIH Advance Directive for Health Care and Medical Research Participationâ€ form so that another person can make decisions about their medical care in the event that they become incapacitated or cognitively impaired during the course of the study. Note: The PI [INVESTIGATOR_74840].  For those subjects that become incapacitated and do not have pre-determined substitute decision maker, the procedures described in MAS Policy 87-4 for appointing a surrogate decision maker for adult subjects who are (a) decisionally impaired, and (b) who do not have a legal guardian or durable power of attorney, will be followed.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
5510.4 Evaluation of Benefits and Risks/Discomforts
The potential benefits of this protocol therapy re main unclear in this population of patients, but 
preliminary data described in the background suggests the potential for benefit in some patients.  
The potential side effect profile of  pembrolizumab is described in Section 11.
10.4.1 Optional Biopsies 
All care will be taken to minimize risks that may be incurred by [CONTACT_62564]. However, there are 
procedure-related risks (such as bleeding, infection a nd visceral injury) that will be explained fully 
during informed consent. If patients suffer any physi cal injury as a result of the biopsies, immediate 
medical treatment is available at the NCIâ€™s Clinical Center in Bethesda, Maryland.
Although no compensation is available, any injury wi ll be fully evaluated and treated in keepi[INVESTIGATOR_517928] e entitled under applicable regulations. 
Some biopsies may be performed with CT guidance. If that is the case, then this research study 
involves exposure to radiation from up to 2 CT scans , at baseline prior to starting treatment and at 
the end of treatment (at 2 years). The effective dose per one CT scan  will be 0.77 rem. This is 
below the guideline of 5.0 rem per year allowed f or research subjects by [CONTACT_517950].
10.5 Risks/Benefits Analysis
This study will enroll a minimally symptomatic adult population with medullary thyroid cancer.  
These patients are generally monitored in conventional practice at this stage as the lack of substantial symptoms from disease negates the need for FDA-approved therapi[INVESTIGATOR_517929].  Although immune related adverse events are possible with this study, they are likely manageable and will not substantiall y impact the quality of life of these patients.  
The potential benefits of pembrolizumab have yet to be determined in medullary thyroid cancer, although preliminary data from a small number of patients described in the background is hypothesis-generating.  Thus in a risk reward analysis (a discussion that will be part of the informed consent process with each patient) this study allows the patients to have an opportunity 
to try a modern immunotherapeutic agent that is FDA approved for other cancers during a therapeutic window of opportunity.
10.[ADDRESS_671860].
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
5610.6.1 Telephone Re-Consent Procedure
Re-consent on this study may be obtained via telephone according to the following procedure: 
the informed consent document will be sent to the subject. An explanation of the study will be provided over the telephone after the subject has had the opportunity to read the consent form. The subject will sign and date the informed consent. A witness to the subjectâ€™s signature [CONTACT_517952].  The original informed consent document will be sent back to the consenting investigator who will sign and date th e consent form with th e date the consent was 
obtained via telephone. A fully executed copy will be returned via mail for the subjectâ€™s records. The informed consent process will be documented on a progress note by [CONTACT_517951] a copy of the informed consent document will be kept in the subjectâ€™s research record.
10.6.2 Informed Consent of Non-English Speaking SubjectsIf there is an unexpected enrollment of a research participant for whom there is no translated 
extant IRB approved consent document, the principal investigator [INVESTIGATOR_1238]/or those authorized to 
obtain informed consent will use the Short Form  Oral Consent Process as described in MAS 
Policy M77-2, OHSRP SOP 12, 45 CFR 46.117 (b) (2), and 21 CFR 50.27 (b) (2).  The 
summary that will be used is the English version of the extant IRB approved consent document.  Signed copi[INVESTIGATOR_446549].
Unless the PI [INVESTIGATOR_74842]â€™s language, an interpreter will be present to 
facilitate the conversation (using either the long translated form or the short form). Preferably someone who is independent of the subject (i.e., not a family member) will assist in presenting information and obtaining consent. Whenever poss ible, interpreters will be provided copi[INVESTIGATOR_338726] (24 to 48 hours if possible). 
We request prospective IRB approval of the use of the short form process for non-English 
speaking subjects and will notify the IRB at the time of continuing review of the frequency of the use of the Short Form.
10.[ADDRESS_671861] 
azoospermia (whether due to having had a vasectomy or due to an underlying medical 
condition).  
Female subjects will be considered of non-reproductive potential if they are either: 
(1) postmenopausal (defined as at least 12 months with no menses without an alternative 
medical cause; in women < 45 years of age a high follicle stimulating hormone (FSH) 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671862]-menopausal state in 
women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.); 
OR 
(2) have had a hysterectomy and/or bilatera l oophorectomy, bilateral salpi[INVESTIGATOR_176715]/occlusion, at least 6 weeks prior to screening; 
OR (3) has a congenital or acquired condition that prevents childbearing.
Female and male subjects of reproductive potential must agree to avoid becoming pregnant or 
impregnating a partner, respectively, while receiving study drug and for [ADDRESS_671863] dose of study drug by [CONTACT_139649]:  
(1) practice abstinence
â€ from heterosexual activity; 
OR 
(2) use (or have their partner use) acceptable contraception during heterosexual activity.  
Acceptable methods of contraception areâ€¡:
Single method (one of the following is acceptable):
xintrauterine device (IUD)
xvasectomy of a female subjectâ€™s male partner 
xcontraceptive rod implanted into the skin
Combination method (requires use of two of the following):
xdiaphragm with spermicide (cannot be used in conjunction with cervical cap/spermicide)
xcervical cap with spermicide (nulliparous women only)
xcontraceptive sponge (nulliparous women only) 
xmale condom or female condom (cannot be used together)
xhormonal contraceptive: oral contraceptive pi[INVESTIGATOR_4382] (estrogen/progestin pi[INVESTIGATOR_64870]-only 
pi[INVESTIGATOR_4382]), contraceptive skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection
â€ Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if 
it is consistently employed as the subjectâ€™s preferred and usual lifestyle and if considered acceptable by [CONTACT_176742]/IRBs.  Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception. 
â€¡If a contraceptive method listed above is restricted by [CONTACT_427]/guidelines, then it does 
not qualify as an acceptable method of contraception for subjects participating at sites in this 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
58country/region.
Subjects should be informed that taking the study medication may involve unknown risks to the 
fetus (unborn baby) if pregnancy were to occur during the study.  In order to participate in the study subjects of childbearing potential must adhere to the contraception requirement (described above) from the day of study medication initiation (or 14 days prior to the initiation of study medication for oral contraception) throughout the study period up to [ADDRESS_671864]â€™s status until the pregnancy has been completed or terminated.  The outcome of the pregnancy will be reported to th e study PI [INVESTIGATOR_458510] 
24 hours to the study PI [INVESTIGATOR_295760] 2 working days to [COMPANY_006] if the outcome is a serious adverse experience (e.g., death, abortion, congenital anomaly, or other disabling or life-threatening complication to the mother or newborn).  
The study PI [INVESTIGATOR_517930]. If a ma le subject impregnates his female partner the 
study personnel at the site must be informed immediately and the pregnancy reported to the 
study PI [INVESTIGATOR_517931] 7.3.[ADDRESS_671865]-feeding are not eligible for enrollment.
11 PHARMACEUTICAL INFORMATION  
11.1 Pembrolizumab (MK-3475)11.1.1 SourcePembrolizumab will be provided to the NCI pha rmacy as part of a clinical trial agreement.
There will be no IND obtained for the use of Pembrolizumab in this study.  This study meets the 
criteria for exemption for an IND as this investigation is not intended to support a new indication for use or any other significant change to the labeling; the drug is already approved and marketed and the investigation is not intended to support a significant change in advertising; and the investigation does not involve a route of administration or dosage level in use in a patient population or other factor that significantly increases the risks (or decreases the acceptability of the risks) associated with the use of the drug product.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
5911.1.2 Toxicity
xImmune-mediated pneumonitis, including fata l cases, occurred in patients receiving 
pembrolizumab. Pneumonitis occurred in 32 (2.0%) of 1567 patients, including Grade 1 
(0.8%), 2 (0.8%), and 3 (0.4%) pneumonitis. Monitor patients for signs and symptoms of 
pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneum onitis. Withhold pembrolizumab for Grade 2; 
permanently discontinue pembrolizumab fo r Grade 3 or 4 or recurrent Grade 2
pneumonitis. 
xImmune-mediated colitis occurred in 31 (2%) of 1567 patients, including Grade 2 (0.5%), 
3 (1.1%), and 4 (0.1%) colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold pembrolizumab for 
Grade 2 or 3; permanently discontinue pembrolizumab for Grade 4 colitis. 
xImmune-mediated hepatitis occurred in 16 (1%) of 1567 patients, including Grade 2 
(0.1%), 3 (0.7%), and 4 (0.1%) hepatitis. Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or great er hepatitis and, based on severity of liver 
enzyme elevations, withhold or  discontinue pembrolizumab. 
xHypophysitis occurred in 13 (0.8%) of 1567 patients, including Grade 2 (0.3%), 3 (0.3%), and 4 (0.1%) hypophysitis. Monitor patients for signs and symptoms of hypophysitis (including hypopi[INVESTIGATOR_44791]). Administer corticosteroids and hormone replacemen t as clinically indicated. Withhold 
pembrolizumab for Grade 2; withhold or di scontinue for Grade 3 or 4 hypophysitis. 
xHyperthyroidism occurred in 51 (3.3%) of 1567 patients, including Grade 2 (0.6%) and 3 (0.1%) hyperthyroidism. Hypothyroidism occurred in 127 (8.1%) of 1567 patients, including Grade 3 (0.1%) hypothyroidism. Thyroid disorders can occur at any time during treatment. Monitor patients for change s in thyroid function (at the start of 
treatment, periodically during treatment, and as indicated ba sed on clinical evaluation) 
and for clinical signs and symptoms of thyroid disorders. Administer replacement hormones for hypothyroidism and manage hype rthyroidism with thionamides and beta-
blockers as appropriate. Withhold or discontinue pembrolizumab
Â®(pembrolizumab) for 
Grade 3 or 4 hyperthyroidism. 
xType 1 diabetes mellitus, including diabetic  ketoacidosis, occurred in 3 (0.1%) of 2117 
patients. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Administer insulin for type 1 diabetes, a nd withhold pembrolizumab and administer anti-
hyperglycemics in patients with severe hyperglycemia. 
xImmune-mediated nephritis occurred in 7 (0.4%) of 1567 patients, including Grade 2 
(0.2%), 3 (0.2%), and 4 (0.1%) nephritis. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold pembrolizumab for 
Grade 2; permanently discontinue pemb rolizumab for Grade 3 or 4 nephritis. 
xOther clinically important immune-mediated a dverse reactions can occur. For suspected 
immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the seve rity of the adverse reaction, withhold 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671866] 1 month. Based on limited data from clinical studies in patients whos e immune-related adverse reactions could not 
be controlled with corticosteroid us e, administration of other systemic 
immunosuppressants can be cons idered. Resume pembrolizumab when the adverse 
reaction remains at Grade 1 or less following corticosteroid taper. Permanently discontinue pembrolizumab for any Grade 3 immune-mediated adverse reaction that 
recurs and for any life-threatening immune-mediated adverse reaction. 
xThe following clinically significant, immune-mediated adverse reactions occurred in less than 1% (unless otherwise indicated) of 1567 patients: arthritis (1.6%), exfoliative 
dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-BarrÃ© syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma. 
xSevere and life-threatening infusion-related re actions have been reported in 3 (0.1%) of 
[ADDRESS_671867] dose of pembrolizumab. 
xIn Trial 6, pembrolizumab was discontinued due to adverse reactions in 9% of 555 
patients; adverse reactions leading to disc ontinuation in more th an one patient were 
colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy 
(0.4%), and cardiac failure (0.4%). Advers e reactions leading to interruption of 
SHPEUROL]XPDERFFXUUHGLQRISD WLHQWVWKHPRVWFRPPRQÂ• ZDVGLDU[LOCATION_006]HD
(2.5%). The most common adverse reactions with pembrolizumab vs ipi[INVESTIGATOR_517932] (28% vs 28%), diarrhea (26% with pembrolizumab), rash (24% vs 23%), and nausea (21% with pembrolizumab). Corresponding incidence rates are listed for ipi[INVESTIGATOR_517933]. 
xIn Trial 2, pembrolizumab was discontinued due to adverse reactions in 12% of 357 
SDWLHQWVWKHPRVWFRPPRQÂ• ZHUHJHQHUDOSK\VLFDOKHDOWKGH WHULRUDWLRQ
asthenia (1%), dyspnea (1%), pneumonitis (1%), and generalized edema (1%). Adverse reactions leading to interruption of pembrolizum ab occurred in 14% of patients; the most 
FRPPRQÂ•ZHUHG\VSQHDGLDU[LOCATION_006]HDDQGPDFXOR-papular rash (1%). The most common adverse reactions with pembro lizumab vs chemotherapy were fatigue 
(43% with pembrolizumab), prur itus (28% vs 8%), rash (24%  vs 8%), constipation (22% 
vs 20%), nausea (22% with pembrolizumab ), diarrhea (20% vs 20%), and decreased 
appetite (20% with pembrolizumab). Corresponding incidence rates are listed for 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671868] Name & Potency Dosage Form
Pembrolizumab 50 mg Lyophilized Powder for Injection
Pembrolizumab 100 mg/ 4mL Solution for Injection
11.1.[ADDRESS_671869] does not contain a preservative.
xStore the reconstituted and diluted solution from the pembrolizumab 50 mg vial either: 
oAt room temperature for no more than 6 hours from the time of reconstitution. This 
includes room temperature storage of reconstituted vials, storage of the infusion solution in the IV bag, and the duration of infusion.
oUnder refrigeration at 2Â°C to 8Â°C (36F to 46F) for no more than 24 hours from the time of reconstitution. If refrigerated, allow the diluted solution to come to room temperature prior to administration.
xStore the diluted solution from the pembrolizumab 100 mg/4 mL vial either: 
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
62oAt room temperature for no more than 6 hours from the time of dilution. This 
includes room temperature storage of the infusion solution in the IV bag, and the duration of infusion.
oUnder refrigeration at 2Â°C to 8Â°C (36F to 46F) for no more than 24 hours from the time of dilution. If refrigerated, allow the diluted solution to come to room temperature prior to administration.
xDo not freeze.
11.1.5 Administration procedures
Reconstitution of pembrolizumab f or Injection (Lyophilized Powder)
xPembrolizumab is administered through a 0.2 to 5 micron sterile, nonpyrogenic, low-protein binding inline or add-on filter. Do no t infuse other mediations through the same 
infusion line.
xAdd 2.3 mL of Sterile Water for Injection, USP by  [CONTACT_240338] (resulting concentration 25mg/mL).
xSlowly swirl the vial. Allow up to 5minutes f or the bubbles to clear. Do not shake the vial
xPreparation for Intravenous Infusion
xVisually inspect the solution for particulate ma tter and discoloration prior to administration. 
The solution is clear to slightly opalescent, colo rless to slightly yellow. Discard the vial if 
visible particles are observed.
xDilute pembrolizumab injection (solution) or reconstituted lyophilized powder prior to 
intravenous administration.
xWithdraw the required volume from the vial(s) of pembrolizumab and transfer into an 
intravenous (IV) bag containing 0.9% Sodium Chloride Injection, USP or 5%
xDextrose Injection, USP. Mix di luted solution by [CONTACT_5237]. The final concentration of 
the diluted solution should be between 1mg/mL to 10mg/mL.
xDiscard any unused portion left in the vial.
11.1.[ADDRESS_671870] been conducted with pembrolizumab.11.1.7 Clinical Supplies DisclosureThis trial is open-label; therefore, the subject, the trial site personnel, the Sponsor and/or 
designee are not blinded to treatment. Drug identity (name, strength) is included in the label text; random code/disclosure envelopes or lists are not provided.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
6311.1.8 Returns and Reconciliation
The investigator is responsible for keepi[INVESTIGATOR_246080], the amount dispensed to and returned by [CONTACT_110535]. 
Upon completion or termination of the study, all unu sed and/or partially used investigational 
product will be destroyed at the site per institutional policy. It is the Investigatorâ€™s responsibility
to arrange for disposal of all empty containers, provided that procedures for proper disposal have been established according to applicable federal, state, local and institutional guidelines and procedures, and provided that appropriate records of disposal are kept.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
6412 APPENDIX A: PERFORMANCE STATUS CRITERIA
ECOG Performance Status Scale Karnofsky Performance Scale
Grade Descriptions Percent Description
0Normal activity.  Fully active, 
able to carry on all pre-disease performance without restriction.100Normal, no complaints, no evidence of disease.
90Able to carry on normal activity; minor signs or symptoms of disease.
1Symptoms, but ambulatory.  Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).80Normal activity with effort; some signs or symptoms of disease.
70Cares for self, unable to carry on normal activity or to do active work.
2In bed <50% of the time.  Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up and about more than 50% of waking hours.60Requires occasional assistance, but is able to care for most of his/her needs.
50Requires considerable assistance and frequent medical care.
3In bed >50% of the time.  Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.40Disabled, requires special care and assistance.
30Severely disabled, hospi[INVESTIGATOR_374].  Death not imminent.
4100% bedridden.  Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair.20Very sick, hospi[INVESTIGATOR_374]. Death not imminent.
10Moribund, fatal processes progressing rapi[INVESTIGATOR_375].
5 Dead. 0 Dead.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
6513 APPENDIX B: INSTRUCTIONS FOR PRE-STUDY AND FOLLOW-UP BLOOD
TESTS
Blood Studies Blood T ube/Comments Destination
CBC, with 1 purple top Clinical Center Lab
differential Bldg. 10
BUN, Creatinine 1 gold top Hem/Onc Lab
SGOT, Alk. Phos, Bldg. 10
Bilirubin, Albumin  
(chem. 20), TSH
Serum for HIV 1 gold top Hem/Onc Lab
Antibody HIV Consent Bldg. 10
Immunology Assays   6 10-cc green tops NCI-Frederick (Leidos)           
[ADDRESS_671871] (tiger) top tubes ([PHONE_4244])
T/B/NK 1 purple top Clinical Center Lab
(lymphocyte subsets) Bldg 10
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/18
6614 REFERENCES
1. Mahoney KM, Atkins MB. Prognostic and predictive markers for the new 
immunotherapi[INVESTIGATOR_014]. Oncology (Williston Park). 2014;[ADDRESS_671872] 3:39-48.
2. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of 
the clinical features and prognostic factors in 161 patients. Medicine (Baltimore). 
1984;63(6):319-342.
3. Hamy A, Pessaux P, Mirallie E, et al. Central neck dissection in the management of 
sporadic medullary thyroid microcarcinoma. Eur J Surg Oncol. 2005;31(7):774-777.
4. Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for 
medullary thyroid carcinoma. World J Surg. 2008;32(5):754-765.
5. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of 
the American Thyroid Association. Thyroid. 2009;19(6):565-612.
6. Sherman SI. Advances in chemotherapy of differentiated epi[INVESTIGATOR_517934]. J Clin Endocrinol Metab. 2009;94(5):1493-1499.
7. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of 
doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid 
carcinoma. Cancer. 1985;56(9):2155-2160.
8. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of 
KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 
2002;62(24):7284-7290.
9. Wells SA, Jr., Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with 
locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 
2010;28(5):767-772.
10. Wells SA, Jr., Robinson BG, Gagel RF, et al. Vandetanib in patients with locally 
advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134-141.
11. Administration UFaD. FDA approves new treatment for rare form of thyroid cancer. 
2011; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250168.htm .
Accessed July 7, 2012.
12. Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary 
thyroid cancer. J Clin Oncol. 2013;31(29):3639-3646.
13. Bilusic M, Heery CR, Arlen PM, et al. Phase I trial of a recombinant yeast-CEA vaccine 
(GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer immunology, 
immunotherapy : CII. 2014;63(3):225-234.
14. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature 
reviews. Cancer. 2012;12(4):252-264.
Abbreviated Title: Pembrolizumab in MTC
Version Date: 3/26/[ADDRESS_671873] clinical outcome. Science. 2006;313(5795):1960-
1964.
16. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosi s: the potential link 
between conventional cancer therapy and immunity. Exp Biol Med (Maywood). 
2011;236(5):567-579.
17. Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ. Preclinical evidence 
that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of 
established tumors. Cancer Res. 2014;74(15):4042-4052.
18. Antoni R, Caroline RF, Hodi S, et al. Association of response to programmed death 
receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 33, 2015 (suppl; abstr 3001) 
19. Ismailov SI, Pi[INVESTIGATOR_517935]. Postoperative calcitonin study in medullary thyroid 
carcinoma. Endocrine-related cancer. 2004;11(2):357-363.
20. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with 
pembrolizumab in ipi[INVESTIGATOR_125]-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-1117.
21. Sadow PM, Hunt JL. Mixed Medullary-follicular-derived carcinomas of the thyroid 
gland. Advances in anatomic pathology. 2010;17(4):282-285.
22. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy 
activity in solid tumors: immune-related response criteria. Clin Cancer Res. 
2009;15(23):7412-7420.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.